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ABSTRACT  
Tumor initiation and progression are dependent on both aberrant gene expression in tumor cells 
and the communication between tumor cells and its micro- and systemic environments. Many 
tumor suppressor genes and oncogenes have been characterized to suppress or promote tumor 
growth, but fewer genes in tumors are well-characterized as interacting with immune cells in the 
host to promote or inhibit tumor growth. The interleukin (IL) 27 receptor WSX1 is expressed in 
immune cells and induces an IL27-dependent immune response. Opposing this conventional 
dogma, our initial results reveal a much higher level of WSX1 expression in multiple types of 
epithelial tumor cells when compared to normal epithelial cells. These revelations suggest a role 
for WSX1 in tumor development, and thus a possible target in cancer immune-therapy. Using 
genetically modified tumor cells, our studies show that the expression of WSX1 in tumor cells 
regulates the communication between tumor and host cells resulting in two different 
consequences. In both the cervical cell line TC1 and the squamous carcinoma cell line AT84, 
overexpression of WSX1inhibited tumorigenicity both in vivo and in vitro. Sensitizing NK cell-
mediated surveillance through upregulation of NKG2D ligands in tumor cells is the underlying 
mechanism by which WSX1 inhibits tumor growth.  Further investigations into other cell lines, 
such as colon cancer (CT26) and Lewis Lungs Carcinoma (LLC), confirmed the role of WSX1 
as a tumor suppressor in vitro. In contrast to the role that WSX1 plays in the aforementioned 
cells, aggressive LLC and melanoma AGS tumor cells expressing WSX1 grow faster than the 
control cohorts. These studies reveal that the principal mechanism by which WSX1 promotes 
tumor growth is the inhibition of T cell proliferation and production of the effector cytokine 
IFNγ both in the tumor microenvironment and distal lymphatic tissues. Our evidence reveals that 
this effect is initiated via direct tumor cell and immune cell contact. This important observation 
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reveals a new pathway of tumor-host interaction, which will ultimately lead to better strategies in 
immune therapy to reverse tumor tolerance. 
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CHAPTER 1 
ROLE OF IL12 FAMILY IN REGULATION OF ANTITUMOR IMMUNE RESPONSE* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Reprinted with kind permission of Springer Science + Business Media. 
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INTRODUCTION 
 
Tumor eradication or progression is dependent on interaction and communication with 
immune cells. Such a crosstalk between tumors and immune cells is partially conducted through 
cytokines. In reality, tumor microenvironment is frequently immunosuppressive and contributes 
to a state of immune tolerance(1). As such, delivery of potent immune enhancer cytokines such 
as IL12 may reverse immune tolerance, because IL12 is a potent proinflammatory 
immunoregulatory cytokine that plays a central role in tumor eradication via induction of IFNγ 
and cytotoxic T lymphocytes (2). IL12 therapy was successful in a variety of murine models (3-
5). Although a promising immunotherapeutic agent, excess toxicity in preclinical trials is 
associated with systemic delivery of IL12 (6).   Decreasing the amount of IL12 administration 
reduces its therapeutic efficiency. Only immunogenic cancers are susceptible to this cytokine, 
therefore, local expressions of this cytokine in the tumor microenvironment or alternative 
cytokines are needed in cancer therapy.  
IL12 family is composed of IL12, IL23, IL27 and IL35. Although within the same 
family, these cytokines have different functions. IL12 is the key cytokine that promotes TH1 
differentiation, while IL23 promotes TH17 (2, 7). IL35 enhances T regulatory functions, while 
IL27 exert pro and anti-inflammatory functions (8). Interestingly, these family members exert 
such diverse functions while at the same time share many receptors and subunits among each 
other. As such, IL12 and IL23 share subunit p40 and IL12Rβ1, IL27 and IL35 share subunit 
EBI3 and gp130 receptor, while IL12 and IL35 share p35 and IL12Rβ2 (9). Many reviews have 
described heavily how these cytokines affect autoimmune diseases (10-12). In addition, others 
have described how these cytokine affect the immune cells (13, 14). But the literature lacks 
reviews that focus on how IL12 family member signal in tumors and how they affect the 
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crosstalk between tumors and immune cell.  In summary, this review focused on the expression 
and function of IL12 family members and the cognate receptors in tumors, and how these 
cytokines affect T regulatory cells (Tregs).  
ABERRANT EXPRESSION OF IL12 FAMILY MEMBER RECEPTORS AND 
SUBUNITS 
 
The IL12 cytokine family is composed of IL12, IL-27 and IL-23 and IL35. IL-27 is a 
heterodimeric cytokine that consists of EBI3, an IL12p40-related protein, and p28, a newly 
discovered IL12p35-related polypeptide (15). IL-27 is produced by dendritic cells, monocytes 
and endothelial cells (16, 17). This cytokine exerts its biological functions through the 
heterodimeric receptor WSX1/TCCR and gp130 (18). While gp130 is ubiquitously expressed 
and receptor of other cytokines such as IL-6, WSX1 is specific for IL-27(19). WSX1 is 
expressed mainly in monocytes, dendritic cells, T and B lymphocytes, NK cells, mast cells, and 
endothelial cells (18). 
Recent discoveries have found that subunits or receptors of the IL12 family members are 
expressed not only in immune cells but also in tumor cells. Tumors have many ways to outfox 
the immune system, such as retention of certain receptors while eliminating others, or 
modulating the downstream signaling of a receptor. IL23 subunits p19 and p40 are upregulated 
in multiple human cancers such as colon, ovarian, head and neck, lung, breast, stomach and 
melanoma cancers (20).  IL12 has not been upregulated in these tumors, as IL12p35 expression 
in tumors was similar to adjacent tissues. We have shown that WSX1 is expressed and functional 
in human breast cancer cells (21), while others later have confirmed its expression in human 
melanoma cells (22) and leukemia cells (23). In addition to the IL27 receptor WSX1, the EBI3 
subunit of IL27 is expressed in a variety of blood-related tumors (24-26). We will carefully 
examine the role that each subunit/receptor plays.  
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While in epithelial cells overexpression of WSX1 delayed IL27-mediated tumor cell 
proliferation (22), WSX1 expression in leukemia cells transformed two leukemia cell line, 32D 
and BaF3, by eliciting antiapoptotic and mitogenic signals(23).  Overexpression of WSX1 not 
only induces cytokine (IL3)-independent growth, but also activates Jak2, ERK1/2 and STAT5, 
all markers of acute myeloid leukemia (AML) transformation. However, the activation of these 
genes via WSX1 is not the determining factor to induce cell transformation. The key factor is the 
presence of point-mutation of Jak2 at V167F (27-29). WSX1-dependent transformation of the 
leukemia cells is dependent upon activation of JAK2-V617F. The co-expression of WSX1 and 
mutated JaK2, but not wildtype JAK2, results in phosporylation of STAT3 and JAK2. Therefore 
overexpression of WSX1 does not per se transform cells, but acts as a scaffold receptor to 
activate tumor cells with already mutated JAK’s. On the contrary to the leukemia cells lines, 
overexpression of WSX1 in melanomas enhances IL27-mediated antiproliferative activities (22). 
Enhanced signaling of IL27/WSX1 signaling is dependent on the presence of STAT1 and 
upregulation of MHC class I. IL27 signaling also enhances transcription factor IRF1 and IRF8 
expression. IL27-mediated delayed tumor growth is partially dependent on IRF1, as 
downregulation of IRF1 with siRNA partially reversed the aforementioned process (22).  As 
synopsis, human and mouse melanoma cells downregulate WSX1 as a mechanism to enhance 
cell survival. 
The Pradhan group also showed that WSX1-dependent transformation of the leukemia 
cells is independent of gp130 and IL27, as gp130 is not expressed in the tested leukemia cells 
(30). They also show the IL27 downstream signaling is inhibited, in accordance with other 
publications, showing that IL27 needs a heterodimeric receptor to signal(31). As the study in the 
melanoma cells showed the protective role of IL27/WSX1 signaling, the study in leukemia cells 
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did not evaluate the role of IL27 signaling by overexpression of the missing receptor gp130 on 
these WSX1-transformed leukemia cells.  One possibility is that leukemia cells downregulate 
gp130 while maintaining WSX1, therefore inhibiting IL27 signaling while preserving scaffold 
receptor WSX1.  
Not only IL27 receptor WSX1 is expressed in dissociation to gp130 in cancers, but also 
its subunit EBI3  is selectively expressed in dissociation to p28 in a series of Epstesin-Barr Virus 
(EBV) and Human T cell Leukemia virus (HTLV) type associated lymphomas (26). EBV-Virus 
associated lymphomas are associated with several human malignancies such as Burkitt 
lymphoma, Hodgkin lymphoma and nasopharyngeal carcinoma (32). Although these tumors 
express antigen presenting molecules such as HLA-1, immune costimulatory molecules such as 
CD80 and CD86, and are susceptible to CTL in-vitro, cytotoxic T-cell specific against EBV are 
rarely found on patients’ lymph nodes  (33). One question is how these tumors downregulate 
immune surveillance. IL10 is one of the cytokines associated with the immunosuppressive 
environment in EBV-positive tumor cells (34). Another possible factor associated with EBV-
derived tumors is the IL27-EBI3 subunit. EBI3 is a downstream factor of NFkB activation and 
its expression is associated with other oncogenes responsible for T cell transformation such as 
LMP1 and Tax(26). Nearly 90% of tumor cells in each case tested from Hodgkin’s lymphoma 
patients were positive for EBI3, but only 5% were positive for p28 subunits.  Similarly, in EBV-
associated lymphoproliferative disorders (EBV- LPD’s), EBI3 was expressed at high levels, 
whereas p28 or IL27 were not detected. In addition, EBI3 levels were detected in follicular 
lymphomas and in diffuse large B-cell lymphomas of both germinal centre  and non-germinal B-
cell like types (25). Also, EBI3 was overexpressed in a subset of adult T-cell leukemias that are 
dependent on IL2. These lymphomas upregulate EBI3 and express significant levels of the 
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WSX1 receptor, but lack p28, a necessary subunit to form a bioactive IL27 (26). Although 
normal T cells express EBI3 after activation, these levels are 16 times lower than HTLV-positive 
T cells. Interestingly, the EBI3 expression level in EBV-LPD’s was correlated with LMP1, an 
oncogene that plays a role in EBV-mediated growth transformation. EBI3 induction in HTLV 
positive T cells is dependent on NFkB activation via Tax protein, which plays an important role 
in T cell transformation. The inhibition of NFkB signaling reduces EBI3 expression only in the 
presence of wildtype Tax, but not mutated Tax (which is defective in NFkB activation)  (26). 
These studies suggest that EBI3 is a downstream factor of oncogenes that are associated with 
lymphoma transformation and might play a role in tumor progression and immune evasion.  
Another independent study revealed that EBI3 is expressed in Hodgkin’s lymphoma and 
nasopharyngeal carcinoma (24). In addition to EBI3, IL12p35 was also expressed (IL12p40 
subunit was not expressed). In light of new discoveries of IL35 as an immunosuppressive 
cytokine associated with inhibiting effector T cell function, composed of EBI3/p35, it seems 
logical that immune evasion of these lymphoma cells would be attributed to IL35 function.  In 
accordance, others have indicated that nasopharyngeal carcinoma cells are not capable of 
inducing IL12p70 (35). These findings suggest that EBV HTLV-type associated lymphomas 
selectively modulate IL12 family members by enhancing EBI3 and/or p35 while downregulating 
p40 and/or p28 to attain a favorable tumor microenvironment. 
The dissociated expression of EBI3 and p35 expression is not observed only in a 
pathogenic scenario, but is also found in normal settings such as in intestinal tract (36). The 
intestinal tract is the initial contact site between host and pathogens. In a balanced system, 
proinflammatory signals are balanced with anti-inflammatory signals. Overexpression of 
proinflammatory cytokines, such as IL12, in this environment would result in an autoimmune 
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disease. Defining the mechanism on how the intestinal tract differentiates between pathogenic 
and commensial bacteria is of crucial importance. It would, not only provide insight into the 
control processes in the peripheral tolerance, but also it would indicate several potentially 
important therapeutic targets. One potential use of these targets would be cancer, since immune 
cells develop tolerance towards tumor cells. Human mucosal epithelial cells produce EBI3, 
IL12p35 and IL23p19, but not their counterpart subunits, such as p28 and IL12p40 that are 
necessary to form bioactive and functional IL12, IL27 and IL23. Proinflammatory mediators 
such as IL1α and TNFα induce EBI3 and p19, but not IL12p35 (36). On the other hand, p35 is 
induced after IFNγ response and its expression was delayed when compared to EBI3 and p19.  
This model suggests that in a balanced system such as the intestinal tract, induction of p35 to 
make a functionally IL35 is pushed to a later time point. Therefore, only after a prominent cell-
mediated immune response are both subunits of IL35 induced.  
IL27 signaling in tumors is inhibited by dissociated and/or aberrant expression of its 
receptor WSX1 and gp130 (21-23). As mentioned above, one possibility is that certain tumors 
preferentially lower one or the other receptor as a mechanism to enhance cell survival. Although 
modulation of IL27 receptors in tumors might be useful therapeutically, clinical translation as a 
therapy would require further investigation on (I) what are the pathways that are activated by 
WSX1 receptor, and (II) what are the critical pathways activated by this receptor are 
malfunctioning in tumor-bearing patients. As further mechanisms are needed to establish how 
this receptor activates downstream pathways in either epithelial or blood-related tumors, 
nonetheless its therapeutic potential is promising.  
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ROLE OF IL23 IN TUMORS 
IL23 is another member of IL12 family. This cytokine is a composed of two subunits: 
p19 and p40 (9). While IL23 shares p40 and receptor IL12Rβ1 with IL12, they drive quite 
different immune pathways. As IL12 drives the classical IFNγ pathway, IL23 is an essential 
factors required for the expansion already committed TH17 cells into pathogenic cells (37). 
Although many reviews and research articles have focused on the role of IL23 is autoimmune 
diseases, fewer articles have focused on role of IL23 in cancers (38-40).  
The role of IL23 in tumor biology is dichotomous. While lack of IL23 showed protection 
against tumor initiation, IL23 used as a therapeutic or vaccine adjuvant reduced tumor growth 
(20, 41, 42). In order to study the role of IL23 expression in epithelial tumorigenesis, the authors 
tested susceptibility of IL12p35-/-, IL12/23p40-/-, and IL23p19-/- mice to tumor formation during 
cancer progression (20). Mice lacking IL23 subunits p19 and p40, but not p35 were resistant to 
tumor initiation and papilloma formation. Reduced tumor initiation in IL23 deficient mice was 
consistent with reduction of inflammatory markers, which are essential for tumor promotion such 
as IL17, GCSF, MMP9 and CD31. Another interesting factor is that lack of IL23 in the tumor 
microenvironment enhanced CD8 infiltration in vivo. Lack of CD8 T cell infiltration was 
dependent on IL23, as intradermal injection of IL23 reduced CD8 T cell infiltration, while IL12 
enhanced CD8 infiltration as previously observed (43).  
Contrary to the discovery described above, local and systemic administration of IL23 
reduces tumor growth. Local overexpression of single chain IL23 in cell lines such as 
immunogenic CT26 grew in balb/c mice, but then spontaneously regressed in a CD8 T cell 
dependent matter (41). This same phenomena was also observed using a poorly immunogenic 
melanoma cell line such as B16F10(42). IL23 mediated tumor growth inhibition was dependent 
on CD8 and IFNγ production. In another study by Overwijk, overexpression of IL23 in non-
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immunogenic B16 tumors did not show tumor growth inhibition. Nonetheless this group studied 
how IL23 could be used as an adjuvant to vaccination of already established non-immunogenic 
melanoma tumors (44). They used a gp100 peptide vaccination after adoptively transferring 
antigen-specific pmel CD8 T cells towards this peptide. IL23 aided tumor suppression by 
vaccine-induced T cells and enhanced function of intratumoral T cells. The enhanced T cell 
effector functions were characterized by high ability of antigen specific CD8 T cells to produce 
IFNγ without need of in-vitro stimulation with the peptide. Although IL23 enhances IFNγ 
production of tumor specific T cells, they concludes that IFNγ production by CD8 T cells does 
not have a major role in enhancing IL23 role as an adjuvant; adoptive transfer of IFNγ-/- pmel T 
cells still remain responsive to IL23 therapy. In contrary to this statement that IFNγ is 
dispensable, others have shown that IFNγ is absolutely necessary for IL23 anti-tumor activity 
(45). In IFNγ knockout mice, IL23 antitumor effects were non-existent and partially abrogated in 
IL12 KO mice. In addition, this study shows that IL23 administered systemically reduces tumor 
growth and is dependent on CD4, CD8, and partially on NK cells. The authors suggest that once  
TH1 response is fully established, only then IL23 does exert its potent antitumor activity. This 
claim is not in disagreement with Overwijk study since their argument solely depends on IFNγ-/- 
CD8 transfer, but not on the endogenous IFNγ. In summary, IFNγ is primarily involved in IL23-
mediated antitumor activities while IFNγ production from CD8 is dispensable in this process. 
Further conclusive studies are needed to elucidate whether prevalence of TH1 response is 
necessary to mediate IL23 antitumor response and molecular mechanism associated with it. 
IL23 mediated antitumor effects are observed not only in mouse tumor models, but also 
in a human pancreatic cancer cell lines such as AsPC (46). Interestingly, AsPC overexpressing 
IL23 showed retarded tumor growth in nude mice, but not in SCID mice. In addition, depletion 
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with anti-asialo GM1 antibody did not affect tumor growth inhibition in nude mice. In this 
particular tumor model, IL23 mediates its antitumor effect mainly through γδ T and/or NKT 
cells.  
One of the downfalls using IL23 systemically is weight loss. This toxicity is dependent 
on expression of TNFα (44). Depletion of TNFα reduces side effects; nonetheless it’s not 
feasible as it mediates not only weight loss, but also anti-tumor activity. Therefore local rather 
than systemic administration of this cytokine would improve its antitumor activities as a direct 
immune stimulator or as a vaccine adjuvant. Indeed, local expression of IL23 augmented 
vaccine-induced antitumor activity without weight loss. 
Contradictory to the aforementioned role of IL23 as an anticancer therapeutic 
agent/adjuvant, IL23 expression in the microenvironment enhances tumor growth partially by 
activating a tumor-promoting inflammation and angiogenesis. It is well known that IL23 
promotes pathogenic TH17 lineage. It also promotes tissue restructuring and neovascularization, 
all tumor-adopted strategies to thrive and grow. To explain the contradictory role of IL23, these 
authors suggest that high expression of IL23 in the tumor microenvironment induces an 
overwhelming myeloid infiltration of DC, macrophage and granulocytes that destroy tumors 
(40). Others indicate that a TH1 priming microenvironment in the host is necessary for systemic 
delivery of IL23 to eradicate tumors as IL23 was non-effective to eradicate tumors in INFγ-/- 
mice (45). IFNγ also has been shown to downregulate TH17 while promoting TH1 induction  
(47, 48). It is also reasonable to assume that exogenous IL23 can serve as a potent 
adjuvant/therapeutic anticancer agent to enhance an-already established but probably weak 
TH1/IFNγ immune response. On the other hand, endogenous IL23 produced at the local 
microenvironment, together with other inflammation promoting agents from tumors such as 
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TGFβ, might reroute the immune response toward more of wound-healing tumor-promoting 
TH17.  
ROLE OF IL27 IN TUMORS 
One of the earlier functions attributed to this cytokine is its ability to synergetic induction 
of IFNγ with IL12, and proliferation of naive CD4+T cells (15). IL-27 also induces T-bet 
expression and IL12Rβ expression, key components to TH1 commitment, through STAT-1(49). 
Given its role in initiation of TH1 response and induction of IL12 receptor, several researchers 
evaluated the role of IL-27 in cancer immunotherapy. Function of IL-27 was examined in 
different tumor models such as: colon cancer 26 (CT26), neuroblastoma (TBJ), and aggressive 
melanoma (B16F10)(50-54)  
IL-27 possesses T-cell and NK cell mediated antitumor activities. In immunogenic colon 
cancer system IL-27 mediated antitumor activities mainly though CD8 T cells and epitope-
specific CTL. Immunogenic CT26 overexpressing IL27 showed reduced tumor growth in vivo. 
IL27 expression induced IFNγ and increased CTL against CT26 cells. The mechanism was 
dependent on CD8 and IFNγ, since antitumor activity was abolished in nude mice or mice 
depleted for IFNγ and CD8. Interestengly, in Tbet-/- mice, IL27 did not display any antitumor 
activities(55). Not only CD8+ T cells, but also other subsets of T  and NK cells account for IL-27 
antitumor properties. In nude mice, CT26-IL27 tumor growth was retarded when compared to 
parent CT26; this phenomena was partially reversed upon administration of anti-asialo GM1 
depletion antibody(50). Therefore possibly γδ T cells or NKT mediated antitumor effect. In 
highly aggressive melanoma B1F10, NK cells were mainly involved(53).  
Hisada and Chiyo (2004, 2005) show that IL27 uses different subsets of immune cells to 
eradicate the same tumor model CT26 such as T and γδ/NKT respectively. The difference 
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between these studies relies on different cell number and different amount of IL27 
expression/cell. This suggests that higher amounts of IL27 in the microenvironment employ 
wider subsets of immune cells. Also this study shows that overexpression of either subunit alone 
does not enhance mice survival, but expression of both subunits does so, suggesting that IL27 
but not its particular subunits are necessary for antitumor activity.   
IL27 antitumor activity does not depend on either STAT4 or IL12(56). Since IL27 
exerted antitumor effects in either IL12p40 or STAT4 knockout mice, IL12 is not necessary of 
IL27-mediated antitumor activity. In contrast to IL27, IL23 is partially dependent upon IL12 to 
exert antitumor activity(45). The mechanism associated with IL27 as an anticancer agent 
depends upon CTL induction and enhancement of cytolytic molecules such as granzyme B and 
perforin(56). STAT1 was the important transcription factor necessary for induction of T-bet, 
IL12Rβ2, perforin, granzyme B and synergestic induction of IFNγ with IL12(56). While T-bet 
was important for induction of IL12Rβ2, perforin, granzyme B and synergestic induction of 
IFNγ with IL12, this transcription factor was not important for enhanced CTL activity, as in 
Tbet-/- mice IL27 enhanced allogeneic CTL activity in a dose dependent matter comparable to 
Wt mice (56). Although IL27 increased CTL activity in a Tbet independent matter, this 
transcription factor is important for IL27 mediated antitumor activities in vivo, as tumors grew 
much faster in Tbet-/- mice but not in Wt mice. This phenomena could be explained by a later 
study which emphasizes that Tbet and WSX1 expression in CD8 T cells are indispensable for 
IFNγ production in CD8 T cells  in vivo but not in-vitro (57).  
In neuroblastoma TBJ cell line, overexpression of IL27 eradicated more than 90% or 
tumors and rendered these mice resistant to tumor challenge(58). TBJ27 but not control TBJ 
reduced adjacent parental tumor cells. IL27 overexpression conferred tumor memory not only on 
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neuroblastoma, but also in another independent tumor model such as CT26(55).  In addition to 
inducing tumor memory, overexpression of this cytokine in the tumor microenvironment also 
reduced metastasis of primary. TBJ27 reduced number of metastatic tumor in the liver and 
furthermore, 40 % of the mice were tumor free of their metastatic tumors. The mechanism 
responsible for IL27 mediated tumor regression was dependent on CD8 but not NK or CD4 was. 
IL27 also enhanced IFNγ and MHC class I in the tumor microenvironment(58). Such great 
antitumor effect associated with IL27 production in the tumor could be attributed not only to 
IL27 signaling in the host, but also in the tumor itself. Although this study did not determine 
WSX1 levels on TBJ cell line, enhanced MHC class I induction in the tumor environment 
suggests the presence of a functional WSX1.  
IL27 antitumor effect has been shown not only in immunogenic models such as CT26 
and neuroblastoma, but also on B16F10, a mouse melanoma that is a model of poor 
immunogenicity characterized by a low MHC class I expression. B16F10 that overexpress single 
chain IL27 show reduced tumor growth not only toward primary tumors, but also against 
pulmonary metastasis (59). Interestingly, IL27-mediated antimetastatic activities were not 
dependent only on the host as T, B, and NK deficient mice still retained tumor growth inhibition. 
The authors also showed that IL27 enhanced expression of antiangiogenic markers such IP10, 
MIG while it reduced in-vivo angiogenesis. What seems to be quite impressing is that IL27 acts 
independently of IFNγ to induce anti-angiogenesis markers. Even in IFNγ-/- mice, B16F10-IL27 
showed reduced tumor growth and metastasis. Similarly, another group using the same tumor 
model B16F10 showed that IL27 exerts antitumor activities in absence of IFNγ (42). This 
phenomenon is quite different from IL12 and IL23 as both these cytokines depend on IFNγ to 
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induce antitumor activity (45). It also seems that IL27, a downstream molecule of IFNγ and IL12 
might act in synergy or independently of IL12 to suppress tumor growth.  
As we have previously seen, IL27 antitumor effects are not only attributed to signaling in 
tumors or immune cells, but also to vascular endothelial cells that surround tumor 
microenvironment (59, 60). Endothelial cells have a dual role during tumor progression either 
promoting or inhibiting tumor growth. Endothelial cells act as a support matrix in tumors, and 
provide many growth factors to tumors through enhancing angiogenesis. On the other hand, 
endothelial cells can function as antigen-presenting cells and can upregulate MHC class I and II 
to aid in T cells in CTL activity (61).  In addition, they can upregulate certain receptors to recruit 
innate immune cells(62). The balance between anti and pro-tumor environment depends on 
cytokine balance secreted by the tumor and/or present there. IL-27 receptor WSX1 was present 
in endothelial cells and IL27 signaling directly on endothelial cells has increased anti-angiogenic 
molecules such as IP10 and MIG (59). IL27 also upregulated MHC class II and MHC class I 
together with microglobulin and Tap genes(60). It also increases fractaline expression in 
endothelial cells, a chemokine that attracts and activates CX3CR1 NK positive cells and DC 
cells (63, 64). Activation of NK and maturation of DC cells in the local microenvironment leads 
to an enhanced expression of IL12 and IFNγ, both factors necessary to tip the microenvironment 
balance towards an antitumor response.  
IL27 overexpression exerts antitumor effects not only in mouse carcinoma, but also in 
human oesophageal carcinoma Eca cell line (65). When injected into nude mice, Eca cells 
overexpressing IL27 showed a retarded tumor growth and enhanced survival. As associated to 
previous tumor models, NK cells from mice overexpressing IL27 showed an increased IFNγ 
production and increase cytolytic activities when compared to splenocytes from control mice. 
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The retarded tumor growth could not be due to direct effect of IL27 signaling into the tumor 
cells, as IL27 did not increase MHC class I or reduced cell proliferation. While IL27 showed an 
increase in NK cell function, IL27 did not increase NK cell infiltration or NK cell activation 
marker CD69 (65). Although IL27 has been shown to increase antiangiogenic markers MIG and 
IP10 in other reports (59), this study showed no change in IP10, MIG or vessel number. As one 
possibility could be that IFNγ induction in nude mice is limited, although other reports show that 
IL27 can has anticancer properties independent of IFNγ (42, 59). Once again, this suggests that 
IL27 employs different antitumor pathways depending on the tumor microenvironment that 
particular tumors create.  
Contradictory to aforementioned role of IL27 in reduce tumor growth, this cytokine has 
been shown to have anti-inflammatory role. Other groups have shown that IL27 receptor 
knockout mice have a prolonged cytokine expression, while DC have a prolonged expression of 
activation markers CD80/86 after LPS stimulation(66). In  addition, IL27 directly downregulated 
these activation markers in LPS-stimulated DC. Also IL27 receptor WSX1 was upregulated in 
DC cells after LPS stimulation. IL27 also downregulates IL2 production in activated T cells. 
These authors propose a model that IL27/WSX1 delivers little inhibitory signals at the initial 
immune response, while at later phases upregulation of IL27/WSX1 promotes more profound 
inhibitory functions. In an in-vivo tumor model this model does not hold true as constant IL27 
expression enhanced NK and T cells functions. Immature dendritic cells reside primarily in 
peripheral tissues where they uptake antigens and process it, while mature DC cells reside in the 
lymphoid tissue to interact with antigen-specific T cells. One of the problems associated with 
tumor microenvironment is lack of maturation DC such as in human breast, ovarian, and prostate 
cancers(67). These immature DC rarely leave the tumor environment to mature and travel to the 
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lymphoid organs as tumor-associated factors such as IL-10, TGFβ, VEGF inhibit DC cell 
differentiation (68, 69). Therefore, the role of IL27 to downregulate activation markers would 
mean that these DC need to be matured in the first place. 
ROLE OF IL12 FAMILY IN TREG CELLS 
T regulatory cells are part of the T cell repertoire that keep the immune system in check 
by inhibiting proliferation and function of T cells and attenuating responses against self and non-
self. There are two types of Treg cells: naturally occurring Treg cells that are generated in the 
thymus, and inducible Treg which are generated in the periphery from naïve T cells via 
TGFβ(70-72). Treg cells express Foxp3, transcription factor that controls both development and 
function of these cells (73). Besides Foxp3 Tregs, there are other types of regulatory T cells such 
as Tr1 and TH3 also contribute to suppression in the periphery. Tr1 and TH3 are characterized by 
secretion of immunosuppressive IL10 and TGFβ, respectively (74, 75).  In a clinical setting, high 
number Treg’s is an indication of poor prognosis for cancer patients (76-78). Many tumors 
enhance number of iTregs as a mechanism to evade tumor recognition. A high accumulation of 
Treg’s in the tumor microenvironment, lymph nodes or blood is not a result of high trafficking 
into these areas, but rather is a result of proliferation and de-novo induction(79). TGFβ is a key 
player in this process, as it increases the proliferation as well as the induction of de-novo Treg 
cells. Tumors release TGFβ or induce immature DCs to release TGFβ that can enhance the 
number of Tregs (80). Tregs not only suppress CD8 T cells proliferation, but also inhibit NK cell 
function (79). Tregs and TGFβ inhibit NK cell cytolysis, IL12 mediated IFNγ secretion and 
NKG2D expression.  
The IL12-associated cytokines modulate induction and function of Tregs. Induction of 
Foxp3+ Treg cell via TGFβ is completely inhibited by IL6 (81, 82). The combination of IL6 and 
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TGFβ diverts induction of Foxp3 Tregs into TH17 cells. Not only IL6, but also IL27 has a 
prominent role in induction of Tregs. Recent reports have shown that IL27 not only suppressed 
TH17 induction via TGFβ and IL6, but also suppress number of inducible regulatory T cells in 
vitro (83, 84).  IL27 suppresses TGFβ-induced number of Treg in a dose and time- dependent 
manner. This suppression was not dependent on either IL2 or STAT1 as high doses of 
recombinant IL2 did not rescue IL27 mediated suppression of iTreg while IL27 retained iTreg 
suppression in STAT1-/- splenocytes (83). 
Although IL27 suppresses induction of iTreg, lack of IL27 does not attenuate naturally 
occurring Treg cells as WSX1-/- mice and Wt mice have a similar number of Treg cells(85, 86), 
In addition, EBI3 deficiency does not affect the population of Foxp3 CD25+ Tcells. Moreover, 
IL27 itself does not aid Tregs in suppression of Tcell proliferation. In a classical Treg functional 
assay WSX1-/- Tregs suppressed T cell proliferation in the same manner as wildtype cells in the 
presence or absence of IL27(81). Thus, IL27 seems to play a role not in T cells development or 
function, but rather plays a role during Treg induction.   
In addition to Foxp3 inducible Tregs, other regulatory T cells such as Tr1 contribute to 
active suppression in the periphery (Fig. 1.1). Tr1 cells express IL10 and these cells exert their 
immune suppression mainly through this cytokine (87). IL27 not only suppresses the induction 
TGFβ-mediated iTregs, but also enhances generation of Tr1 like cells to produce IL10 (88). The 
presence of TGFβ produced from Tregs converts immature Dc cells into tolerogenic ones. These 
modified DC produce IL27 and TGFβ. Production of IL27 and TGFβ by these tolerogenic DC 
cells in turn converts T effector cells to produce IL10. Other groups also confirmed that IL27 
upregulated IL10 expression in CD4 and CD8 effector cells (89). Interestingly, IL27 enhances 
production of IL10 in these cells only once activation of T cells has occurred.  
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Not only IL27 neutralizes TGFβ effect on Treg, but it also neutralizes IL6-induced T cell 
hyperproliferation (81). IL6 renders effector T cell refractory to Treg cell-mediated suppression 
while inducing hyperproliferation of these cells (90). Therefore, although IL6 and IL27 share the 
same receptor, these cytokines exert different functions. 
 
Figure 1.1.  IL12 family affects different pathways of immune system  
The mechanistic cues on how IL27 in some instances promotes a pro-inflammatory 
environment by reducing Treg numbers(83, 84), while on other’s promotes an anti-inflammatory 
by neutralizing IL6-induced T cell proliferation and inducing Tr1 cells still needs to be 
clarified(81, 88, 89). Probably timing and state of T cells dictates the role of IL27. IL27 priming 
of naïve CD4T cells inhibits Treg induction, resulting in a pro-inflammatory environment; 
addition of this cytokine later on when the Treg cells are already acquired Fox3p enhances Treg 
function indirectly by converting IL-6 mediated refractory T cells into T cells susceptible to Treg 
cytolysis. In addition, production of IL27 in presence of TGFβ gears effector cells towards 
production of IL10. Therefore IL27 has opposing roles during different stages of an immune 
response. 
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 Many questions need to be answered on the role of IL27 in Tregs. First, Villarino at al 
shows that WSX1 expression is modulated during an immune response. IL27 receptor, WSX1 is 
increased not only in activated T cells and memory T cells, but also on Treg CD62LhighCD25high 
when compared to naïve CD62LhighCD25low (85) . Although others have shown that IL27 does 
not affect Treg suppression, why is there a higher expression in Tregs rather than in naïve T cell. 
Next, there is no evidence whether IL27 suppresses inducible Tregs in vivo or whether IL27 
exerts antitumor effects partially by effecting Tregs. Although many authors and studies have 
described IL27 as a future candidate for cancer therapies, caution should be made when 
interpreting these studies. The timing of expressing of IL27 will determine whether IL27 
suppresses or enhances regulatory T cells. Primarily, most studies use tumors transduced with 
single chain overexpressing IL27, thus expressing this cytokine at the initial stage of mounting 
an immune response. Presence of IL27 at the initial stage establishes TH1 proinflammatory 
environment. There are no studies showing the prophylactic properties of IL27 administration 
after tumor establishment. Systemic delivery of IL27 has little to no effect on already established 
tumors (our, unpublished data). In such, the tumors that are clinically detectable have already 
established an immunosuppressive environment characterized by presence of Tregs. In this 
prospective, IL27 might promote an immunosuppressive environment. Therefore, use of IL27 as 
a therapeutic agent alone might not be effective. Administration of IL27 in addition with Treg 
suppressor such as cyclophosphamide might prove a synergistic effect. The timing and sequence 
of administration between these two agents should be considered as well. The first phase should 
consist of cyclohexamine, followed by IL27 after a lag period. In the presence of lower Tregs, 
IL27 might stimulate T cells and NK to produce cytotoxic molecules against tumors.  The lag 
period should provide enough stimulus to revert the immune-suppressive tumor environment at 
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least for a short time. In addition, the lag period should be in reverse proportion to tumor size and 
aggressiveness. In other words, the lag period in aggressive tumors models should be shorter 
than immunogenic tumors. Also, lower number of Treg cells would translate in fewer tolerogenic 
DC’s; therefore there is less chance that IL27 might enhance induction of Tr1 cells. In light of 
new anti-inflammatory properties, further in-depth studies are needed to explore the anticancer 
role of IL27.  
ROLE OF IL35 IN TUMOR AND IMMUNE CELLS  
The ever-growing complex IL12 family just acquired a new cytokine IL35 to increase 
ways in which modulates and shapes the immune system (8). IL35 is composed of IL27 subunit 
EBI3 and IL12p35, a complex already known but with no attributable function (91). EBI3 was 
shown to be a downstream gene induced by Foxp3. From all the alpha chain cytokines of IL12 
family that are expressed, only p35 and EBI3, but not p19 or p28 are expressed by Treg cells. 
Treg cells upregulate this cytokine only during active suppression of T cells while in contact 
with T effector cells, suggesting that close proximity to Teff is required for induction in trans of 
this cytokine(92). IL35 suppresses effector T cell proliferation and IFNγ production in response 
to activation in a antigen-specific and non-specific manner (8). Downregulation in either subunit 
might be necessary to reduce IL35 suppressive activity, as either subunit alone does not suppress 
proliferation of effector T cells.  
IL35 expression may not be constricted only to Treg, as APC do induce all subunits of 
IL12 family. Although both IL27 and IL35 compete for EBI3, the only known preferential 
expression difference these two cytokines is location, as IL27 is mainly constraint to APC’s 
while IL35 is to Treg cells. Moreover, since EBI3 is shared by IL27 and IL35, and TCCR-/- mice 
display a different phenotype than EBI3-/- mice in T cell-mediated hepatitis (93, 94), then caution 
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should be used when interpreting results from these two different strains. Further studies are 
needed to establish the mechanism necessary to produce one cytokine over another in APC. In 
addition, future studies should elucidate whether APC produce IL35 and whether it exerts 
immunosuppressive role during APC-T cell interaction.  
STATEMENT OF THE PROBLEM AND SPECIFIC AIMS 
 While the function of IL-27 receptor WSX1 in immune cells is well-studied, the function 
of this receptor in tumor cells is not well characterized. Also, the function of the receptor WSX1 
is exclusively associated with IL27 and IL27’s role in immune cells, thus an IL27-independent 
function and its association with cancer biology is largely unknown. Our initial results reveal a 
much higher level of WSX1 expression in multiple types of human epithelial tumor cells when 
compared to normal epithelial cells. Moreover, the high level of WSX1 expression in epithelial 
tumor cells does not correlate to the IL-27-mediated STAT1 phosphorylation in these cells. 
These preliminary data led to our hypothesis that WSX1 has a function in tumor development 
independently of IL-27, and thus a possible target in cancer immune-therapy. 
 In order to explore the function of WSX1 in tumor biology, we performed a series of in 
vivo and in vitro experiments. 
Aim 1: Determine if IL27 receptor WSX1 affects tumor growth.  
Aim 2: Investigate whether WSX1 has a function in tumor biology independently of IL27. 
Aim 3: Understand the mechanism via which WSX1 affects tumor growth. 
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CHAPTER 2 
EXPRESSION OF WSX1 IN TUMORS SENSITIZES IL27-SIGNALING 
INDEPENDENT NK CELLS SURVEILLANCE* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Reprinted with kind permission of Journal of Cancer Research. 
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INTRODUCTION 
IL27 receptor WSX1 is most homologous to the IL12 receptor 2 chain (1). WSX1 
together with gp130 constitute a functional signal-transducing receptor for IL27, whereas lack of 
either subunit attenuates IL27-mediated signaling (2). WSX1 is reported to be expressed in 
immune cells such as monocytes, dendritic cells, T and B lymphocytes, NK cells, mast cells, and 
endothelial cells (1). 
In a patent application (PCT/2007/0280905), we reveal that WSX1 is detectable in breast 
epithelial tumor cells. This discovery is further supported by a recent report which revealed that   
WSX1 is expressed in another type of epithelial tumor, melanoma cells (3).  The same as found 
in immune cells, WSX1 is functional in these epithelial tumors cells as indicated by the IL27-
mediated activation of STAT1 and STAT3 (3). 
Clearly, the reports found in the literature suggest that WSX1 plays a role through the 
IL27 signaling pathway, but the IL27-independent role of WSX1 in promotion or inhibition of 
tumorigenesis has not been reported yet. Using genetically modified tumor cells, we present 
evidence that the expression of WSX1 in epithelial tumor cells suppresses tumor growth both in 
vitro and in vivo. Such inhibition of tumor growth is dependent on NK cells but independent of 
IL27 signaling. Our results reveal a novel function of WSX1 in epithelial tumor cells, which is to 
sensitize NK-mediated antitumor immunosurveillance in an IL27-independent manner. 
MATERIALS  
Cell culture and reagents. Human cancer cell lines from different tissue origins 
including Hela, HT29, HCT116 and 4T1 were purchased from ATCC. Human breast cancer cell 
lines MDA468, MDA231, and MCF7 were provided by Dr. Bolin Liu (University of Colorado 
Denver School of Medicine at Aurora, CO). The normal colon cell line NCM460 was purchased 
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from INCELL Cooperation, LLC. UM-SCC11A, UM-SCC11B, UM-SCC17A, and UM-
SCC17B are head and neck squamous cell carcinomas provided by Dr. Thomas Carey 
(University of Michigan, Ann Arbor, MI) (4). Mouse HPV-associated tumor cell line TC1 was 
provided by Dr. T. C. Wu (John Hopkins University, Baltimore, MD) (5).The mouse squamous 
cell carcinoma cell line AT84 was provided by Dr. Edward Shillitoe (State University of New 
York Upstate Medical School, Syracuse, NY). Recombinant mouse IL27, NKG2D/Fc, 
monoclonal anti-human WSX1, and anti-human MICA-Pe antibody were purchased from R&D 
Systems. Anti-mouse pSTAT1-701, anti-mouse IgG-PE, actin, anti-human IgG-PE, and anti-
hamster IgG-PE were purchased from Santa Cruz Biotechnology. Anti-NKG2D C7 was provided 
by Dr. Wayne Yokoyama (Washington University School of Medicine, St. Louis, MO).   
Quantitative real-time PCR. Total RNA was isolated from cells using TRIzol Reagent 
(Invitrogen). Residual genomic DNA was removed from total RNA using the TURBO DNA-
free™ kit (Applied Biosystems/Ambion). Two micrograms of RNA were used for cDNA 
synthesis using the High Capacity RNA-to-cDNA Kit (Applied Biosystems). The relative gene 
expression levels were determined using quantitative Real-time PCR and SYBR green labeling 
method in an ABI 7300 Sequence Detector (Applied Biosystems). The reaction contained 2 μL 
of cDNA, 12.5 μL the SYBR Green PCR Master Mix (Applied Biosystems), and 200-250 nM of 
primer in a total volume of 25 μL.  The PCR cycling conditions were as follows: 40 cycles of 15 
s at 95°C, 60 s at 60°C. All samples were run in duplicates. PCR amplification of ß-actin was 
performed using 0.1 μL of cDNA. The CT value of each sample was acquired, and the relative 
level of gene expression was calculated by the Delta CT method, which was normalized to the 
endogenous control of ß-actin.  Data were expressed as an n-fold relative to control. The forward 
and reverse primer sequences for the human ß-actin and WSX1 detection are: 
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5’AGAGGGAAATCGTGCGTGAC3’ and 5’CAATAGTGATGACCTGGCCGT3’, 
respectively. WSX1: 5’GAGCCCCCTCCGAGTTACAC3’ (forward) and 
5’AGCTGTTCCCGAGGAATGG3’ (reverse). 
Establishing stable WSX1 expressing cell lines. The murine WSX1 gene was 
purchased from Open Biosystems and subcloned into pBMN-GFP plasmid (Phoenix™ 
Retrovirus Expression System, Orbigen, Inc.). The retrovirus was produced by transfecting 
mWSX1/GFP constructs into Phoenix eco packaging cells. AT84 and TC1 cells were infected 
with retroviral containing supernatant derived from the transduced HEK293 cells. The 
transduction was confirmed by detecting green fluorescent protein (GFP) expressing cells under 
the fluorescence microscope. Cell colonies with GFP expression from a single cell were picked, 
expanded, and further confirmed for WSX1 expression using Flow Cytometry. Using this 
approach, both WSX1/GFP and GFP positive TC1 and AT84 cells were obtained.  
Animal procedures. All the animal procedures were approved by the IACUC at 
Louisiana State University. Six- to eight-week-old mice were used for this study.  The 
subcutaneous tumor models were generated by subcutaneously inoculating TC1 and AT84 tumor 
cells (2x105 in a 30-µL volume per mouse) into mice. Tumor measurement and calculation were 
the same as described previously (6). C57Bl/6 WSX1 knockout mice were provided by Dr. Fred 
de Sauvage (Genentech), and C57Bl/6 EBI3 knockout mice were provided by Dr. Mark P. 
Birkenbach (Temple University School of Medicine, Philadelphia, PA). C57Bl/6, Balb/c SCID, 
C3H, C57Bl/6 perforin, and Rag deficient mice were purchased from commercial sources.  
NK cytotoxicity assay. NK cell activity was evaluated using the CyToxiLux kit 
(OncoImmunin,Inc.), a single-cell-based fluorogenic cytotoxicity assay (7, 8). Effector cells 
were prepared from spleens as previously described (8) and incubated with red fluorescence-
33 
 
labeled target cells at a ratio 100:1, 50:1, and 25:1 in 200 µL cell culture media. Target cells 
alone were used as control for spontaneous cell death. Sixteen hours after incubation, adhesive 
target cells were washed with PBS. Alive red target cells (input target cells) were counted using 
Olympus BX41 fluorescence microscope. NK activity was calculated using the following 
equation: % NK cell activity = 100 x (input target cells – output target cells) / (input target cells).   
Flow Cytometry. Cells were stained with the indicated primary and secondary antibodies 
for 30 min at 4˚ as indicated in each figure. The expression of the indicated genes was analyzed 
on FACS Calibur and Cellquest graphics software (BD Biosciences). 
Cell proliferation. Cell proliferation assays were performed using the luminescence ATP 
Lite assay detection system (PerkinElmer). Briefly, 500 cells were seeded in a 96 well plate; 
cells were lysed on days 0, 2, and 4 for measuring the ATP levels. The cell proliferation index 
was calculated using the following equation: Cell proliferation index= [ln (d)] / [ln (d0)], where 
ln (d) = natural log at the day when cells were lysed; ln (d0) = natural log at the day when cells 
were seeded.  
Soft agar growth assay. The clonogenic assay was performed as previously described 
(9). Briefly, genetically engineered cells (5x103 for TC1-GFP  and TC1-WSX1 cells and  1x103 
for AT84-GFP and AT84-WSX1 cells) were suspended in 0.34% agar in cell culture media 
(Sigma, St Louis, MO). The mixture solution was layered on solid agar support prepared from 
0.9% agar in cell culture media. The cells were seeded in triplicates on a 6-well plate and grown 
for 2 weeks. Colonies were counted under a 10x dissecting microscope after staining with 0.05% 
Crystal Violet for 1 h. Images were captured using Molecular Image Gel Dox XR (Biorad). 
Western blot. Cells (5x105), growing in 10% heat-inactivated FBS-containing culture 
media, were treated with or without IL27 (20 ng/mL) for the indicated times. Protein extract was 
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obtained by directly lysing cells using 60 μL of Laemmli sample buffer. Twenty microliters of 
total protein extract from each sample were separated by SDS-PAGE, transferred to a 
nitrocellulose membrane and incubated with primary antibody overnight at 4° C (750x dilution 
for anti-pSTAT1/701 and 1000x fold dilution for anti-Actin). 
Statistical analysis. For in vivo experiments, Univariate Repeated Measures ANOVA 
was used to analyze the difference among treatments using SAS version 9.1.3. When 
appropriate, Tukey’s HSD test was performed for interaction affects. For in vitro results, 
student’s T test analysis was conducted. 
RESULTS 
A much higher level of functional WSX1 is expressed in most of the tested epithelial 
tumor cells than in normal epithelial cells. It is well known that the IL27 receptor WSX1 is 
expressed mainly in immune cells and the only other type of cells expressing this gene is 
endothelial cells. However, recently we and others have found WSX1 expression in breast and 
melanoma epithelial tumor cells lines (3). To determine whether the WSX1 expression in 
epithelial tumor cells plays an important function, we have compared the magnitude of WSX1 
expression between normal and tumor epithelial cells. The quantitative analysis result 
demonstrated that WSX1 was present not only in breast cells but also in colon, cervical, and 
squamous cell carcinoma tumor cells, suggesting that WSX1 was expressed in most human 
epithelial tumor cells (Fig. 2.1A).  However, the expression level of this gene varied greatly 
among the different cell lines when compared to the normal epithelial cell line NCM460 (Fig. 
2.1A). A few cell lines such as HT29 and UM-SCC17A showed 6.9-8.4-fold lower expression of 
WSX1 when compared to a normal epithelial cell line, NCM460, while most of the cell lines 
such as Hela, HCT116, and UM-SCC11A showed much higher levels of expression (ranging 
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from 13-78 times higher than NCM460). The high level of WSX1 expression in most of the 
epithelial tumor cells but not in the normal epithelial cells suggests that WSX1 may play a role in 
regulating tumor progression. The level of WSX1 protein expression was positively associated 
with the level of mRNA (Fig. 2.1B).  
Since WSX1 is the receptor of IL27, one obvious question is whether the high level of 
gene expression is associated with a high level of function. We used phosphorylation of STAT1 
by IL27 as a functional WSX1 end point. After 10 min of incubation with IL27 (the second lane 
in each panel, Fig. 1C), IL27 induced phosphorylation of STAT1; such an increase correlates 
well with the presence of WSX1 expression but does not correlate with the absolute level of 
WSX1 expression (Fig. 2.1B). The human cell lines HT29 and UM-SCC17A lacking WSX1 
expression showed very low to no detectable STAT1 phosphorylation, while cell lines such as 
Hela, HCT116, and UM-SCC11A with WSX1 expression showed an increase in phosphorylation 
of STAT1. However, a similar level of phosphorylation was detected in both the low (NCM460 
and UM-SCC17B) and high (HCT116 and Hela) level WSX1-expressing cells (Fig. 2.1C vs. 
2.1A). 
WSX1 reduces tumorigenecity and proliferation of epithelial tumor cells. The results 
from others exclusively illustrate that WSX1 plays a role in inducing an immune response 
through IL27-signaling in immune cells. The result from Fig. 1B confirms that the IL27/WSX1 
signaling occurs in epithelial tumor cells. However, the high level of WSX1 expression does not 
correlate to the STAT1 phosphorylation in most epithelial tumor cells (Fig. 2.1C). Moreover, the 
endogenous IL27 is undetectable in either serum or splenocytes and, therefore, may not initiate 
any signaling in either tumor or host cells during tumorigenesis and development.  
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Figure 2.1. Quantitative and functional analysis of WSX1 in a variety of human epithelial 
cell lines. A, determination of the level of WSX1 expression using Quantitative Real-time PCR. 
The levels of WSX1 mRNA are normalized to actin mRNA, and the data shown is the relative 
expression of each cell line to HT29. B, detection of WSX1 expression at the protein level via 
flow cytometry. Cells were stained with the isotype control or with anti-human WSX1 antibody 
followed by anti-mouse-PE and median fluorescence intensity (MFI) difference was calculated 
as difference in MFI between isotype control and WSX1-stained cells. C, detection of functional 
WSX1 in tumor cells. Cells were treated with IL27 for 10 min (10’), overnight (o/n), or left 
untreated (m). Cell extracts were analyzed using western blot technique and probed with anti-
pSTAT1 and actin antibodies. 
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These facts suggest that a high level of WSX1 expression alone may affect tumorigenesis, which 
is the central hypothesis to be tested below. 
To determine whether increased WSX1 expression alone may regulate IL27 signaling-
independent tumor development, a clonogenic assay was performed to determine the 
tumorigenecity and proliferative ability of tumor cells engineered with WSX1 or GFP control 
genes. This method has been known to be effective in determining these end points (10). Flow 
cytometry analysis confirmed the expression of WSX1 in the stable transfected cell clones (Fig. 
2.2A).  The clonogenic assay results illustrated that expression of WSX1, but not GFP, 
dramatically reduced the ability of cells to grow in soft agar in both TC1 and AT84 cells (Fig. 
2.2B and 2C).  
To further confirm the inhibitory effect of WSX1 expression on tumor cells, cell 
proliferation was determined. Similar to the clonogenic assay, WSX1 significantly reduced the 
proliferation of TC1 and AT84 cells, but the inhibition of AT84 proliferation by WSX1 
expression was at a much lower magnitude when compared to TC1 (Fig. 2.2D).  
WSX1 suppresses tumor growth in vivo in both TC1 and AT84 tumor models. 
Although the clonogenic assay is a good predictor of tumorigenecity in vitro, it does not read any 
host cell-induced cytotoxic end-points that occur in a true tissue environment (11). To avoid this 
problem, the effect of WSX1 expression on tumor growth was tested in syngeneic mice by 
subcutaneously inoculating with GFP or WSX1-expressing tumor cells. In agreement with the in 
vitro assay result, WSX1 expression almost completely abolished TC1 tumor growth (Fig. 2.3 
A). Likewise, WSX1 expression also inhibited AT84 tumor growth in a different mouse strain 
(Fig. 2.3 B). The remarkable difference in the tumor growth rate shown in TC1 and confirmed in 
AT84 strongly indicates that WSX1 has a tumor suppressive role in epithelial tumor cells.  
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Figure 2.2. WSX1 reduces tumorigenecity and proliferation of epithelial tumor cells. A, 
detection of WSX1 expression in TC1 and AT84 tumor cells with flow cytometry. TC1 and 
AT84 tumor cells were transduced with retroviruses containing either control GFP (gray) or 
WSX1 gene (not shaded). The established stable cell lines were stained with a monoclonal 
WSX1 antibody followed by an anti-hamster-PE antibody. The data is representative of two 
independent clones. B, comparative analysis of soft agar growth assay between GFP and WSX1 
in two different cell lines, TC1 and AT84. The data is representative of two independent clones, 
each performed in triplicate. C, a low-magnification photograph of clones formed of AT84-GFP 
vs. AT84-WSX1. D, GFP and WSX1 positive TC1 and AT84 cells were harvested on indicated 
days and analyzed for ATP release N=4. Error bars are smaller than symbols. Columns, mean; 
bars, SE *, P < 0.05 
 
 WSX1-mediated suppression of tumor growth is dependent on NK cells. The direct 
antitumor mechanism by WSX1 was not found in the literature, but one possible explanation 
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Figure 2.3. WSX1 suppresses tumor growth in vivo in both TC1 and AT84 tumor models. 
A, comparison of tumor growth between TC1-GFP and TC1-WSX1 in C57Bl/6 mice. B, 
comparison of tumor growth between AT84-GFP and AT84-WSX1 in C3H mice, N=4-5. Points, 
mean; bars, SE. *, P < 0.05. 
 
could be due to the reduction of tumor cell proliferation as observed in vitro (Fig. 2.2D). 
However, the dramatic difference in tumor growth in vivo (Fig. 2.3A) when compared to the 
small difference of proliferation in vitro (Fig. 2.2D) between TC1-WSX1 and TC1-GFP 
indicates that cell proliferation differences alone may not be the major cause for the diminished 
tumor growth in the presence of WSX1. An alternative assumption is that WSX1 expression in 
tumor cells may enhance the immune surveillance by the host immune cells. To distinguish 
whether the effect of cell proliferation or the immune system might be the major mechanism that 
accounts for the WSX1-dependent tumor growth inhibition in vivo, we tested tumor growth in 
wild-type, perforin (NK), and Rag (T, B) knockout mice.  
 Similar to wild-type mice, tumor growth reduction between TC1-GFP and TC1-WSX1 
was found also in T and B knockout mice (Fig. 2.4A, left vs. middle). However, the absence of 
perforin almost completely impaired the ability of WSX1 to inhibit tumor growth as there is no 
statistically significant difference in tumor growth between GFP and WSX1 tumors (Fig. 2.4A, 
right). This result suggests that WSX1 may sensitize NK cell surveillance for inhibiting WSX1 
positive tumor growth. To further support this statement, tumors engineered with control GFP 
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gene grew at a similar rate regardless of the presence or absence of NK or T cells (Fig. 2.4B, 
left).  In contrast, WSX1-positive TC1 tumors disappeared in three out of four wild-type mice, 
grew very slowly in T and B deficient mice (reaching 50 mm3 by day 40 after tumor inoculation), 
and developed aggressively in NK deficient mice (averaging 450 mm3  by day 40,  almost nine 
times higher than in T and B knockout mice) (Fig. 2.4B, right). To confirm that this observation 
was not dependent on a single clone, another independent clone (TC1-WSX1-CL2) was tested in 
vivo. Similar to the other engineered WSX1 positive TC1 clone, TC1-WSX1-CL2 was eradicated 
in 4 out of 4 wild-type mice, while it reached 200 mm3 by day 38 in NK deficient mice (Fig. 
2.4C). These findings suggest that our observation is not clone-dependent.  
Similar to the TC1 model, the WSX1-positive AT84 tumor cells grew slower than the 
control AT84-GFP in both the wild-type and T and B cell deficient mice (Fig. 2.4D, left vs. 
middle). To test the WSX1-mediated NK cell dependence for the AT84 tumor model, STAT1 
knockout mice were used because STAT1 is an essential transcription factor for NK cell 
function. In the absence of STAT1, these mice demonstrate impaired NK activity in vitro and fail 
to reject NK-sensitive tumors in vivo (12). As expected, no difference in the growth of control 
and WSX1-positive AT84 tumors was detected in these NK-defective STAT1 deficient mice 
(Fig. 2.4D, right).  
WSX1 suppression of tumor growth is independent of IL27. The presented results 
strongly suggest that WSX1 may play an antitumor role independent of IL27 since the 
endogenous level of IL27 is undetectable in mice. To exclusively confirm the role of IL27, since 
the cooperation among WSX1 expression in tumor cell and NK cell is needed for antitumor 
activity, and IL27 signals in both tumor and immune cells, WSX1-mediated tumor growth 
inhibition was compared in EBI3 knockout mice. Because EBI3 is a subunit of IL27, the lack of 
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Figure 2.4. WSX1-mediated suppression of tumor growth is dependent on NK cells. A, 
comparison of tumor growth between TC1-GFP and TC1-WSX1 in C57Bl/6 wild-type (WT) 
mice (left), Rag (T,B-/-) (middle), and  perforin (NK-/-) knockout mice (right). B, differential 
display of tumor growth rate of TC1-GFP (left) or TC1-WSX1 (right) in different immune 
knockout models such as C57Bl/6 wild-type (WT), Rag (T,B-/-), and perforin (NK-/-) knockout 
mice. C, comparison of tumor growth in C57Bl/6 wild-type (WT) mice and perforin knockout 
(NK-/-) mice for an independent clone of TC1-WSX1 (TC1-WSX1 CL2). D, comparison of 
tumor growth between AT84-GFP and AT84-WSX1 in C3H wild-type (WT) (left), SCID (T,B-/-) 
(middle), and STAT1 (STAT1-/-) knockout mice (right), N=3-5. Points, mean; bars, SE. *, P < 
0.05. 
 
EBI3 would result in inhibition of IL27 signaling in both the host and tumor. As expected, lack  
of endogenous IL27 did not affect WSX1-mediated tumor growth suppression and a similar 
difference in tumor growth between TC1-GFP and TC1-WSX1 was found in wild-type mice as 
was found in IL27 EBI3 knockout mice (Fig. 2.4A left vs. 2.5A).   
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 To further extend this exclusive confirmation, tumor growth in WSX1 knockout mice 
was also tested. Because WSX1 is a specific receptor for IL27, the lack of WSX1 in these mice 
should impede IL27 signaling in the immune cells. Similar to EBI3 knockout mice, WSX1-
mediated tumor growth suppression was retained in WSX1 knockout mice (Fig. 2.5B). 
Moreover, WSX1 positive tumors grow at a similar rate in wild-type, EBI3, and WSX1 knockout 
mice (Fig. 2.5C). These results support our hypothesis that WSX1 retains its ability to impede 
tumor growth in the absence of IL27 signaling in either tumor or host cells.  
WSX1 sensitizes NK cell-surveillance by inducing NKG2D ligand expression in 
tumor cells. Our data above clearly demonstrate that the ability of WSX1 to suppress tumor 
growth is dependent on NK cells and independent of IL27 signaling in either the tumor or the 
host. The question is whether the presence of WSX1 in tumor cells directly sensitizes NK cell-
mediated cytotoxicity. To accomplish this goal, NK cell cytotoxicity was compared between 
TC1-GFP and TC1-WSX1 cells. These assays revealed that TC1-WSX1 cells are more 
efficiently lysed when compared to the TC1-GFP cells (Fig. 2.6A, left). To rule out the role of 
CD8 T cells, we used perforin and Rag knockout splenocytes. Similar to wild-type splenocytes 
(Fig. 2.6A, left), splenocytes from Rag knockout mice lysed TC1-WSX1-positive cells more 
efficiently than TC1-GFP (Fig. 2.6A, middle). Contrarily, the lack of perforin eliminated the 
enhanced cytolytic activity against TC1-WSX1 (Fig. 2.6A, right). Similarly, cytotoxicity against 
AT84-WSX1 was significantly higher than AT84-GFP (Fig. 2.6B). These results indicate that 
WSX1 expression in tumor cells provokes a direct NK cell surveillance.  
One possible hypothesis is that WSX1 increases NK cell cytotoxicity by promoting the 
interaction between tumor cells and NK cells. Given that NKG2D is one of the primary receptors 
that promotes tumor cell surveillance (13), we determined whether the expression of WSX1 in 
43 
 
 
Figure 2.5. WSX1 suppression of tumor growth is independent of IL27. A and B, 
Comparison of tumor growth between TC1-GFP and TC1-WSX1 in (A) EBI3 knockout (EBI3-/-) 
and (B) WSX1 knockout (WSX1 -/-) mice. C, comparison of TC1-WSX1 tumor growth in 
C57Bl/6 (WT), WSX1-/-, and EBI3-/- mice, N= 4-5.  Points, mean; bars, SE. *, P < 0.05. 
 
tumors upregulates expression of NKG2D ligands. Flow cytometry analysis using an NKG2D/Fc 
binding assay (a reagent that detects cell-surface expression of all known NKG2D ligands) 
confirmed the hypothesis that WSX1, but not GFP, greatly enhanced the expression of   
NKG2D ligands (Fig. 2.6C, left and middle). Such ability of WSX1 to induce the expression of 
NKG2D ligands is more pronounced in the TC1 model than in the AT84 model (Fig. 2.6C, 
right). 
 To definitely confirm the hypothesis that upregulation of NKG2D ligands by WSX1 
expression is the central mechanism to enhance NK-mediated cytolytic activity against WSX1 
positive tumor cells, NKG2D receptors on NK cells were blocked using anti-mNKG2D C7 in the 
cytolytic assay (14). As expected, addition of an NKG2D neutralization antibody, anti-mNKG2D 
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Figure 2.6. WSX1 sensitizes NK cell lysis in vitro via an NKG2D pathway. A, NK cell 
activity against TC1-GFP and TC1-WSX1 was analyzed from lymphocytes derived from (A) 
C57Bl/6 wild-type (WT) mice (left), Rag (T,B-/-) (middle), and perforin (NK-/-) knockout mice 
(right). Viable target cells from triplicate wells were counted using a fluorescence microscope. B, 
NK cell activity against AT84-GFP vs. AT84-WSX1 was analyzed from lymphocytes derived 
from SCID mice (T,B-/-). The graphs represent data from three independent experiments. C, 
comparison of NKG2D ligands expression in TC1 (left) and AT84 (middle) tumor cells 
transduced with GFP (gray) or WSX1 gene (not shaded). The indicated cells were stained with 
NKG2D/Fc followed by anti-human IgG-PE and fold induction in MFI was calculated between 
each pair (right). D, NK cell activity in the presence of anti-NKG2D antibody or isotype control 
against TC1-GFP and TC1-WSX1 (left) at 1:100 target to effector ratio, or AT84-GFP and 
AT84-WSX1 (middle) at 1:25 target to effector ratio. Correlation of WSX1 and MICA 
expression in the human tumor cells indicated in Fig 1. Cells were stained with the isotype 
control, WSX1, or MICA and MFI difference between isotype and WSX1 or MICA antibody 
was plotted (right). The plotted values of MFI for MICA expression were log-transformed. 
Points, mean; bars, SE. *, P < 0.05. 
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C7, substantially reduced NK cell lysis against both TC1-WSX1 and AT84-WSX1 target cells to 
levels comparable of GFP counterparts (Fig. 2.6D, left and middle). Furthermore, WSX1 
expression is strongly correlated (R2= 0.7293) to MICA expression in human cancer cell lines 
(Fig. 2.6D, right). 
DISCUSSION 
Although it is well known that WSX1 is expressed in T and NK cells and is a critical 
receptor for triggering immune responses via IL27 signaling in these cells (1, 2, 15), our recent 
results revealed that WSX1 is also expressed in epithelial tumor cells such as breast tumor cell 
lines, while others have found its expression in human melanoma (3) and leukemia cells (16). 
Neither us nor others have quantified the level of WSX1 expression and compared the level of 
expression between epithelial tumor cells and normal epithelial cells. In this study, using a 
quantitative real-time PCR assay, we surprisingly found that WSX1 is not only expressed in 
most of the tested epithelial cells (8 out of 10), but is also expressed 13- to 78-fold higher than 
normal epithelial cells (Fig. 2.1 A). 
While the function of WSX1 in immune cells has been studied extensively, its function in 
epithelial tumor cells has hardly been studied. In immune cells, it is generally accepted that IL27 
possesses both pro- and anti-inflammatory properties (17-25). For example, IL27 induces key 
components to Th1 commitment such as synergistic induction of IFNγ with IL12, proliferation of 
naive CD4+T cells, induction of T-bet and IL12Rβ expression, and possesses T-cell and NK cell 
mediated antitumor activities (15, 20-25); however, parasitic studies show that the absence of 
WSX1 triggers aberrant cytokine production (26, 27). In contrast to previous studies in immune 
cells, our findings assign a new role to WSX1 in epithelial cancer cell biology, that expression of 
WSX1 inhibits epithelial tumor growth in vitro and in vivo (Figs. 2.1, 2.3, and 2.4). Such an 
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observation was confirmed in two independent tumor models, TC1 and AT84. However, this 
observation is different in tumors derived from immune cells in which WSX1 elicited 
antiapoptotic and mitogenic signals (16) and transformed two leukemia cell lines, 32D and BaF3.  
Different from the recent report in which WSX1 expression in epithelial melanoma cells 
requires IL27 to inhibit its tumor cell proliferation and tumor growth (3),  our results provide a 
strong case of IL27-independent antitumor activity by WSX1  (Fig. 2.2 and 2.5). First, IL27 
independence was demonstrated by our trial showing that WSX1 expression inhibited tumor 
growth in mice that lacked the IL27 subunit EBI3, the same as found in wild-type mice (Fig. 2.5 
A). Second, WSX1 expression in epithelial tumor cells inhibits tumor growth in WSX1 knockout 
mice (Fig. 2.5 B).  
Currently, no linkage between WSX1 expression in tumor cells and NK cell-mediated 
surveillance is reported in the literature. Using two different tumor models, TC1 and AT84, we 
show that WSX1 suppresses tumor growth via NK cells. In perforin and STAT1 knockout mice, 
WSX1-dependent suppression of tumor growth is impaired (Fig. 2.4), while in vitro WSX1 
tumor cells are more sensitive to NK cell cytotoxicity (Fig. 2. 6). Such phenomena are dependent 
on the NKG2D pathway, as the presence of WSX1 directly enhances the expression of NKG2D 
ligands (Fig. 2.6) thereby enhancing NK cell-mediated recognition and release of cytotoxic 
molecules towards tumor cells.  
Considering that WSX1 expression in our tumor models inhibits tumor growth while 
expression of WSX1 in certain leukemia cell lines confers transformation (16), further work is 
needed to investigate the molecular mechanism downstream of WSX1 that leads to opposing 
consequences between epithelial and blood-derived tumors. This link between WSX1 and 
NKG2D ligands, which are the intrinsic sensors of oncogenic transformation that induce innate 
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immunosurveillance (28), suggests that WSX1 expression in epithelial tumor cells might play a 
role to prevent tumorigenesis but was eventually overridden by the defaulted pathway or immune 
escape mechanism. Such a scenario is also seen with the MICA-NKG2D surveillance system in 
which a high level of MICA expression in tumor cells were subjected to NKG2D surveillance 
(29, 30), but this surveillance system was overridden by the aggressive tumors due to the 
development of multiple immune escape mechanisms (31, 32). The connection of WSX1 to 
innate immunosurveillance could explain the observed discrepancy among the two tumor models 
used in this study: WSX1 is more effective in inhibiting tumor growth and increasing NKG2D 
ligand expression in TC1 model, a HPV-transformed normal cell line, than in aggressive AT84 
models, a spontaneously arising oral squamous cell tumor of C3H mice, albeit WSX1 expression 
is higher in AT84 than in TC1.  
  In summary, this study exposed a novel function of WSX1 in epithelial tumor cells, 
linked WSX1 to NK-mediated antitumor immunosurveillance, and, most importantly, revealed 
that WSX1 induces an antitumor function by upregulating the expression of NKG2D ligands and 
this process is independent of the IL27 signaling pathway. 
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INTRODUCTION  
Extensive research done on IL27 indicates that this cytokine plays both an inflammatory 
and anti-inflammatory role in regulating the immune response. Primarily, this cytokine was 
attributed pro-inflammatory properties, as TCCR (IL27 receptor, also known as WSX1) deficient 
mice showed reduced Th1 responses in both in vivo and in vitro assays (1-3). Also, IL27 induced 
T cell proliferation, the expression of IL12 receptor 2, and the Th1 transcription factor T-bet 
and attenuated induction of Treg cells (4-6). Opposite to this pro-inflammatory effect, IL27 is 
also an anti-inflammatory cytokine as it induces IL10 production in T cells (7-10). In multiple 
parasitic and autoimmune disease models, mice lacking WSX1 showed an exacerbated immune 
response and enhanced pro-inflammatory cytokine production (11-14). 
The function of the IL27 receptor WSX1 is exclusively associated to IL27 and IL27’s 
role in immune cells, thus IL27-independent function and its association with cancer biology is 
largely unknown. One reason is that WSX1 is primarily expressed in immune cells such as 
monocytes, dendritic
 
cells, T and B lymphocytes, NK cells, mast cells, (1).  The other reason, 
perhaps, is that WSX1 needs to pair with gp130 to constitute a functional signal-transducing 
receptor for IL27 signaling, whereas lack of either subunit attenuates IL27-mediated signaling 
(15).  
Recently, we have revealed that WSX1 has an important role not only in immune cells 
but also in multiple cancers of epithelial origin via an IL27-signaling-independent pathway (16). 
In TC1 and AT84 tumor cells, overexpression of WSX1 inhibits tumor growth via NK-cell-
dependent immune surveillance in vivo, and this effect is independent of IL27 signaling. This 
discovery is further supported by a recent report which revealed that   WSX1 is expressed in 
another type of epithelial tumor, melanoma cells (17).  
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The findings that WSX1 suppresses tumor growth suggest that the levels of WSX1 
expression in tumors cells should be reduced. Opposite to this assumption, many of the human 
cell lines have a high level of WSX1 expression when compared to a normal control cell line, 
NCM460 (16).  Thus, many facets of this receptor in tumor biology remain to be discovered. 
Using genetically modified tumor cells, we present clear evidence that the expression of WSX1 
in two independent tumor models, such as aggressive Lewis Lung Carcinoma (LLC) and 
melanoma cell line AGS, promotes tumor growth independent of IL27 signaling. The underlying 
mechanism by which WSX1 promotes tumor growth is through inhibition of T cell proliferation 
and inhibition of production of the effector cytokine IFNγ both in the tumor microenvironment 
and distal lymphatic tissues. Our conclusive evidence reveals that this effect is initiated via direct 
tumor cell and immune cell contact. This important discovery reveals a totally new mechanism 
on how tumor cells and host immune cells communicate to promote tumor growth. 
METHODS 
Cell culture and reagents. Mouse cancer cell lines AGS and LLC were kindly provided 
by Dr. William E. Carson (The Ohio State University, Columbus, Ohio) and Dr. Augusto C. 
Ochoa (Louisiana State University, School of Medicine, New Orleans, LA), respectively. 
Recombinant mouse IL27, NKG2D/Fc, and anti-CD3 were purchased from R&D Systems 
(Minneapolis, MN); anti- pSTAT1-701, anti-STAT1, anti-actin, anti-hamster IgG-FITC, and 
anti-hamster IgG-APC from Santa Cruz Biotechnology (Santa Cruz, CA), anti-NKG2D-Pe, anti-
NK1.1-FITC, anti-CD4-APC, anti-CD4-FITC, and anti-CD28 from Biolegend (San Diego, CA); 
anti-CD8-FITC from BD Biosciences (San Jose, CA), and anti-IFNγ-APC, from eBiosciences 
(San Diego, CA). Mouse anti-WSX1 was kindly provided by Dr. Fred de Sauvage (Genentech, 
San Francisco, Ca). RPMI or DMEM media were purchased from Invitrogen (Carlsbad, CA).  
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Establishing stable WSX1 and dominant negative WSX1 (DN-WSX1) expressing 
cell lines. The murine WSX1 full length gene (gene bank # BC032878) was purchased from 
Open Biosystems and subcloned into pBMN-GFP (Phoenix™ Retrovirus Expression System, 
Orbigen, Inc.) for generating the WSX1-IRES-GFP retroviral construct. The murine WSX1 full 
length gene was first subcloned into pDsRed-Express vector (Clontech Laboratories, Inc. 
Mountain View, CA) to make the WSX1-DsRed fusion gene (referred to as fWSX1 throughout the 
manuscript). The fusion gene was subsequently cloned into pBMN-GFP, resulting in the WSX1-
DSRed-IRES-GFP retroviral construct. The Lac Z gene in pBMN-Z plasmid (Phoenix™ 
Retrovirus Expression System, Orbigen, Inc.), was replaced with the WSX1-DsRed fusion gene 
(referred to as rWSX1 throughout the manuscript) from above for generating the WSX1-DSRed 
retroviral construct. WSX1 without cytoplasm domain was PCR amplified from WSX1 gene and 
subcloned to pDsRed-Express to make the WSX1-DN-DsRed fusion gene (referred as DN-WSX1 
throughout the manuscript). The fusion gene was subsequently cloned to pBMN-GFP for 
generating the WSX1DN-DSRed-IRES-GFP retroviral construct. The retrovirus was generated by 
transfecting mWSX1-IRES-GFP, WSX1DN-DSRed-IRES-GFP, or control GFP and DsRed 
constructs into Phoenix Eco packaging cells. LLC and AGS cells were transduced with retrovirus 
containing the gene of interest. The transduction was confirmed by detecting fluorescent cells 
under the fluorescence microscope. To differentiate between transduced and non-transduced 
cells, positive fluorescent cells were sorted using a BD FACS Aria III cell sorter. 
 Animal procedures. All the animal procedures were approved by the IACUC at 
Louisiana State University. Six- to eight-week-old mice were used for this study.  The 
subcutaneous tumor models were generated by subcutaneously inoculating LLC and AGS tumor 
cells (2x10
5
 in a 30-µL volume per mouse) into mice. Tumor measurement and calculation were 
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the same as described previously (18). C57Bl/6 WSX1 (TCCR) knockout mice were provided by 
Dr. Fred de Sauvage (Genentech), and C57Bl/6, and Balb/c SCID, deficient mice were 
purchased from commercial sources.  
Flow Cytometry. Cells were stained with the indicated antibodies for 30 min at 4˚C as 
indicated in each figure. The expression of the indicated genes was analyzed
 
on FACS Calibur 
(BD Biosciences, San Jose, CA) and FCS Express 3 (De Novo Software, Los Angeles, CA). For 
intracellular staining, BD Biosciences intracellular kit was used according to manufacturer’s 
instructions. Caspase 8, Caspase 9, and Annexin V kits were purchased from Biovision 
(Mountain View, Ca), and staining was performed according to manufacturer’s instructions. 
Cell proliferation. Cell proliferation assays were performed using the luminescence ATP 
Lite assay detection system (PerkinElmer, Waltham, Ma). Briefly, 500 cells per well were 
seeded in a 96 well plate; cells were lysed on days 0, 2, 4, and 6 for measuring the ATP levels. 
The cell proliferation index was calculated using the following equation: Cell proliferation 
index= [ln (d)] / [ln (d0)], where ln (d) = natural log at the day when cells were lysed; ln (d0) = 
natural log at the day when cells were seeded.  
Soft agar growth assay. The clonogenic assay was performed as previously described 
(19). Briefly, genetically engineered cells (2x10
3
 for LLC-GFP  and LLC-WSX1 cells) were 
suspended in 0.34% agar in cell culture media (Invitrogen, Carlsbad, CA). The mixture solution 
was layered on solid agar support prepared from 0.9% agar in cell culture media. The cells were 
seeded in triplicates on a 6-well plate and grown for 2 weeks. Colonies were counted under a 10x 
dissecting microscope after staining with 0.05% Crystal Violet for 1 h.  
Western blot. Cells (5x10
5
), growing in 10% heat-inactivated FBS-containing culture 
media, were treated with or without IL27 (20 ng/mL) for the indicated times. Protein extract was 
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obtained by directly lysing cells using 60 μL of Laemmli sample buffer. Twenty microliters of 
total protein extract from each sample were separated by SDS-PAGE, transferred to a 
nitrocellulose membrane and incubated with primary antibody overnight at 4° C (750x dilution 
for anti-pSTAT1/701, 1000x dilution for anti-STAT1, 500x for anti-WSX1, and 1000x fold 
dilution for anti-Actin). 
Statistical analysis. For in vivo experiments, Univariate Repeated Measures ANOVA 
was used to analyze the difference among treatments using SAS version 9.1.3. When 
appropriate, Tukey’s HSD test was performed for interaction affects. For in vitro results, 
student’s T test analysis was conducted. 
Cell harvesting/purifications. Spleens were mashed through a 70 µm cell strainer 
(Fisher) to obtain single cell suspensions. CD3
+
 T cells were purified using negative selection 
according to manufactures instructions (Stem Cell Separation, Vancouver, BC, Canada). 
Splenocytes or CD3
+
 T cells were labeled with 20µM CFSE for 15 minutes at 37ºC (Invitrogen, 
Carlsbad, CA). Tumor-infiltrating lymphocytes were obtained by removing tumors, chopping 
them into pieces, and resuspending the mixture in sterile PBS (without Ca
2+
 and Mg
2+
) in the 
presence of a digestion enzyme mixture of collagenase IV, hyaluronidase V (Sigma-Aldrich, St. 
Louis, MO), and DNase II (Fisher, Pittsburgh, PA).  The tissue/enzyme mixture was placed in a 
shaker at 37ºC for 1-2 hours, and then poured through a 70 µm cell strainer, followed by twice 
washing in PBS with Ca
2+
 and Mg
2+
. After the last wash, the cells were stained for flow 
cytometry. 
 Confocal microscopy. To analyze the distribution of WSX1 within the cell, TC1 and 
LLC cells expressing fWSX1 were seeded onto glass slides and fixed. The slides were visualized 
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and photographed using Leica TCS SP2 confocal microscope at the Microscope Center with the 
help of Dr. Xiaochu Wu. (Louisiana State University School of Veterinary Medicine).   
In vitro co-incubation assays. 2*10
6
 CFSE-labeled or unlabeled splenocytes were co-
incubated with 2*10
5 
tumor cells in a 12 well plate for 72 hours in total of 2 mL RPMI media. 
1*10
6
 CFSE-labeled CD3
+ 
T cell were co-incubated with 1*10
5  
or 2.5*10
4 
tumor cells in a 12 
well plate for 48 hours in total of 2 mL RPMI media, and cells were analyzed for CFSE dilution.  
Lymphocytes or CD3
+ 
T cells were activated with anti-CD3 and anti-CD28 antibodies at 
concentrations of 2.0 µg/mL and 0.5 µg/ml, respectively.  
Adoptive T cell transfer. 5*10
6
 CFSE-labeled CD3
+ 
T were suspended in 100 µL of 
PBS and injected i.v. into mice bearing either LLC-GFP or LLC-WSX1 tumors at 300 mm
3
. The 
mice were sacrificed 16 hours and 6 days post adoptive transfer, tumors were harvested and 
processed via enzyme digestion, and CFSE-positive cells in the tumor microenvironment were 
analyzed via flow cytometry. 
RESULTS 
The paradoxical functions of WSX1 between in vivo and in vitro assays. We have 
previously shown that WSX1 is expressed not only in immune cells as reported by others (1) but 
also in epithelial tumor cells (16). WSX1 expression in tumor cells reduced tumorigenecity and 
cell proliferation in vitro in two different cell lines, AT84 and TC1. We wanted to further extend 
this discovery and determine whether WSX1 has the same function in Lewis Lung Carcinoma 
(LLC). Therefore, LLC cells were engineered to express either WSX1 or control GFP (Fig. 
3.1A). The clonogenic and ATP light assays confirmed our previous discovery and showed a 5-
fold reduction in clonogenic ability when compared to control cohorts (Fig. 3.1B and 3.1C). 
Likewise, the same finding was also observed in CT26 and 4T1 (data not shown). In summary, a 
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total of 5 different cell lines yielded the same result: WSX1 expression in tumor cells inhibits 
tumorigenecity.  
To confirm that WSX1 is properly expressed, the localization of this receptor was 
determined via confocal microscope in LLC or TC1 expressing fWSX1 (full length WSX1 fused 
to DSRed). As expected, the data showed that WSX1 is expressed in the membrane, similarly in 
both TC1 and LLC (Fig. 3.1D). Furthermore, flow cytometry confirmed that there is abundant 
expression of this receptor on the membrane (Fig. 3.1E). 
To test whether the same conclusion can be made in vivo, we compared the tumor growth 
difference between GFP- or WSX1-positive LLC tumor cells. Contrary to the in vitro results and 
the other two tumor models (16), WSX1 promotes tumor growth in LLC (Fig. 3.1F). Similarly, 
WSX1 enhanced tumor growth in another independent tumor model, melanoma cell line AGS 
(Fig. 3.1G). Therefore, the fact that WSX1 promotes tumor growth in two independent tumor 
models suggest that this receptor plays a dual function in tumor development.  
WSX1 promotes tumor growth independently of IL27. Our previous data suggested that 
WSX1 inhibited tumor growth independently of IL27 (16). To determine whether WSX1 is a 
promoter of tumor growth independently of IL27, we assessed tumor growth differences between 
full length WSX1 and dominant negative WSX1 (DN-WSX1, lacking intracellular domain). We 
expected that DN-WSX1 should shut down the ability of IL27 to signal in these cells. If DN-
WSX1-expressing tumors grow slower than full-length WSX1 in wild-type mice, then IL27 
promotes tumor growth; otherwise, IL27 does not explain pro-tumorigenic abilities of WSX1. To 
confirm that IL27 can not signal in DN-WSX1, we determined the ability of IL27 to induce Stat1 
phosphorylation and Stat1 expression. As expected, IL27 is able to signal in full-length WSX1 
expressing cells, while in DN-WSX1 cells IL27 has lost such ability (Fig. 3.2A).  
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Figure 3.1. The paradoxical functions of WSX1 between in vivo and in vitro assays. A, 
detection of WSX1 expression in LLC tumor cells via western blot analysis. LLC tumor cells 
were transduced with retrovirus containing either control GFP or WSX1 gene. Cell extracts of the 
established cell lines were analyzed using western blot techniques and probed with mouse WSX1 
and actin antibodies. B, detection of the role of WSX1 in tumor cell proliferation. GFP or WSX1 
positive LLC cells were harvested on the indicated days and were analyzed for ATP release. 
N=4. Error bars are smaller than symbols. C, comparative analysis of soft agar growth assay 
between LLC-GFP and LLC-WSX1 cells. Data is representative of two independent 
experiments, each experiment performed in triplicate. D, detection of WSX1 expression in LLC 
cells via flow cytometry. Cells transduced with either GFP (shaded in gray) or WSX1 genes (not 
shaded) were stained with monoclonal WSX1 antibody followed by an anti-hamster-PE 
antibody. E, detection of WSX1 localization in the cell. Images of TC1 (left) or LLC (right) cells 
expressing fWSX1 gene were captured using a confocal microscope. F, comparison of tumor 
growth between LLC-GFP and LLC-WSX1 in C57Bl/6 mice, N=4.  G, comparison of tumor 
growth between AGS-GFP and AGS-rWSX1 in C57Bl/6 mice, N=5. Points, mean; bars, SE. *, 
P <0.05. 
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Figure 3.2. WSX1 promotes tumor growth independently of IL27.  A, detection of 
functional and truncated WSX1 in tumor cells. LLC cells expressing GFP, WSX1, or DN-WSX1 
were treated with IL27 for 10 minutes (10’), overnight (24hr), or left untreated (-). Equal 
amounts of cell extracts were analyzed using WB techniques and probed with pSTAT1 and 
STAT1 antibodies. B, comparison of tumor growth between LLC-GFP, LLC-WSX1, and LLC-
DN-WSX1 in wildtype C57Bl/6 mice. N=5. C, comparison of tumor growth between LLC-GFP, 
LLC-WSX1 in TCCR 
-/-
 mice. N=4. Points, mean; bars, SE. *, P <0.05 between LLC-WSX1 and 
LLC-GFP. #, P<0.05 between LLC-DN-WSX1 and LLC-GFP. 
 
In vivo, DN-WSX1-expressing tumors grow faster than either full-length and control 
cohorts, excluding the role of IL27 as a tumor promoter (Fig. 3.2B). Previous studies have shown 
that IL27 possesses anti-tumor activities via signaling in immune cells (20-23). Thus, to exclude 
the possibility that WSX1 would act as a decoy receptor, thereby competing with WSX1-
expressing immune cells for IL27, we compared tumor growth rates between GFP and WSX1-
positive tumors in TCCR
-/-
 mice. An increase in tumor growth rates in WSX1-positive tumors 
compared to control counterparts in TCCR
-/-
 mice (IL27 cannot signal into host) suggests that 
WSX1 expression in tumors does not act as a decoy receptor for IL27 but rather promotes tumor 
growth by itself. Indeed, similar to wildtype mice, WSX1 promotes tumor growth in TCCR
-/-
 
mice (Fig. 3.2C).  
WSX1-mediated tumor growth is NKG2D independent. The NKG2D pathway not 
only plays a role in the anti-tumor immune response but also induces immune escape via 
 61 
 
multiple mechanisms: NKG2D-ligands are shed by Erp5, which results in NKG2D receptor 
internalization in NK
+
 and CD8
+
 cells (24, 25). Similar to soluble NKG2D ligands, the release of 
exosomes from tumor cells downregulates the NKG2D receptor in immune cells (26). Moreover, 
immunosuppressive NKG2D
+
CD4
+ 
cells expand upon ligation with NKG2D ligand and inhibit 
CD4
+
 cell proliferation (27). Since we previously found that WSX1 induces NKG2D ligand 
expression in tumor cells and NKG2D ligand internalization can induce immune tolerance, we 
hypothesized that WSX1 might promote immune-evasion via an NKG2D-dependent pathway. 
Contrary to our previous results, WSX1 does not induce NKG2D ligand upregulation (Fig. 
3.3A). Next, we investigated whether WSX1-positive tumors affected NKG2D expression by 
NK
+
 or CD8
+
 cell in vivo.  Our results showed that there is no significant reduction of NKG2D 
receptor in either NK
+
 or CD8
+
 cells by WSX1; in contrast, WSX1 enhanced expression of the 
NKG2D receptor in these cells (Fig. 3.3B). Moreover, the percentage of immunosuppressive 
NKG2D
+
CD4
+
 T cells is similar between GFP- and WSX1-positive tumors. Studies comparing 
the total cellular (cells were permeabilized) or membrane expression of NKG2D in the 
splenocytes of mice bearing LLC-GFP or LLC-WSX1 revealed that extracellular and total 
cellular NKG2D expression was increased rather than decreased by WSX1 (Fig. 3.3C) 
suggesting that internalization of NKG2D is not the mechanism that explains the pro-tumor 
properties of WSX1.  
WSX1 triggers immunosuppression in the tumor microenvironment and in the 
spleen. WSX1 inhibits tumorigenicity and cell proliferation in vitro, while it promotes tumor 
growth when inoculated subcutaneously in syngeneic mice (Fig. 3.1).  This prompted us to think 
that WSX1 in these tumor cells regulates tumor-host communication, therefore inducing a state 
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Figure 3.3. WSX1-mediated tumor growth is NKG2D independent. A, comparison of 
NKG2D ligand expression in LLC cell transduced with either GFP (shaded gray) or WSX1 (not 
shaded). The indicated cells were stained with NKG2D-Fc followed by anti-human IgG-PE. B, 
comparison of NKG2D expression in NK
+
, CD8
+
, and CD4
+
 cells in the splenocytes of mice 
bearing LLC-GFP or LLC-WSX1 tumors, or mice without tumors. Splenocytes from tumor 
bearing mice were pooled (5 mice/group), processed, and stained with the following antibodies: 
NK1.1-FITC, CD8-FITC, CD4-APC, and NKG2D-PE. C, comparison of membrane-only or total 
cellular expression of NKG2D in the splenocytes of mice bearing LLC-GFP (dotted line) or 
LLC-WSX1 tumors (solid line) or  mice without tumors (shaded in gray). Processed splenocytes 
were either permeabilized (bottom panel, ii) or left untreated (top panel, i) and stained with 
NKG2D-PE antibody. 
 
of immunosuppression and suppression of tumor growth. In other words, such tumor growth 
differences may be diminished in immune-compromised mice. To confirm such a hypothesis, we 
compared tumor growth rates between control, WSX1, and DN-WSX1 expressing tumors in  
immune compromised SCID mice. As seen in Fig. 3.4A, absence of T and B cells completely 
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Figure 3.4. WSX1 triggers immunosuppression in the tumor microenvironment and the 
spleen. A, comparison of tumor growth between LLC-GFP, LLC-WSX1, and LLC-DN-WSX1 
in SCID mice. N=3-4. B, comparison of the number of T cells in the tumor microenvironment 
between LLC-GFP and LLC-WSX1 tumor-bearing mice. Tumors from 5 mice were pooled, 
processed, and then stained with CD3-APC or CD4-PE. C, comparison of the number of immune 
cells in the spleen between mice bearing LLC-GFP or LLC-WSX1 tumors or mice without 
tumors. Splenocytes of tumor-bearing mice were pooled (N=5), processed, and then stained with 
CD3-FITC, CD8-FITC, CD4-APC, and NK1.1-FITC.  N=4. Points, mean; bars, SE. *, P <0.05. 
 
abolished the ability of WSX1 to promote tumor growth. To further support this statement, we 
investigated the phenotype of immune cell infiltration in the tumor microenvironment. The total 
number of CD3
+
 and CD4
+ 
T cells present in the tumor microenvironment was drastically 
reduced in WSX1- positive tumors (Fig. 3.4B).  Such an observation was not due to lack of T 
cells infiltration in tumor microenvironment, as systemic transfer of CFSE-labeled CD3
+
 T cells 
LLC-GFP LLC-WSX1 
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had similar tumor-infiltrating ability 16 hours post-transfer (data not shown). WSX1 does not 
only affect immune cells via paracrine signaling in the local tumor microenvironment, but also in 
an endocrine manner in distal organs such as the spleen. Multiple immune cell populations, 
CD3
+
, CD4
+ 
CD8
+
, and NK
+ 
cells, in the spleen were reduced in LLC-WSX1 tumors, suggesting 
the release of secretable factors. 
WSX1 induces immunosuppression in a cell contact-dependent manner. To further 
characterize how WSX1 regulates immune cells, tumor cells expressing WSX1 or GFP were 
directly co-incubated with splenocytes.  Similar to the in vivo results, the frequency of CD3
+
, 
CD4
+
, CD8
+
, and NK
+ 
cells were reduced by 40-60% in LLC-WSX1 tumors compared to LLC-
GFP in culture systems (Fig. 3.5A). Likewise, WSX1 inhibited the frequency of T and NK cells 
in an independent tumor model, AGS (Fig. 3.5B).  
A hallmark of T and NK cell activation is expression of IFNγ. WSX1-positive tumors 
cells reduced the percentage of CD4
+
 T cells that were producing IFNγ when compared to 
cohorts (3% versus 23.5%) in splenocytes in vitro. Moreover, the percentage of IFNγ+ CD8+ and 
IFNγ+ NK+ cells was also largely decreased in the presence of LLC-WSX1 (Fig. 3.5C) compared 
to the presence of LLC-GFP. This observation was also extended to the AGS model (Fig. 3.5D).  
Although WSX1 affects T and NK cell number and cytokine production, we wanted to 
assess whether WSX1 does so in a contact-dependent manner or via release of secretable factors. 
To answer this question, LLC-tumor cells where co-incubated with splenocytes directly or 
separated via a transwell, and T cell numbers and cytokine production was determined. The use  
of a transwell reversed the ability of WSX1 to induce immunosuppression in T cells (Fig. 3.6A 
and 3.6B), suggesting that WSX1 induces immunosuppression via a direct receptor-receptor 
interaction.  
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Figure 3.5. WSX1 induces immunosuppression in immune cells in a cell contract-dependent 
manner. A, comparison of the effect of LLC-GFP or LLC-WSX1 tumor cells on the number of 
immune cells in vitro. Splenocytes were co-incubated with the tumor cells mentioned above in 
the presence of anti-CD3 and anti-CD28 antibodies for 72 hours and stained with the following 
antibodies: CD3-FITC, CD8-FITC, CD4-FITC, and NK1.1-FITC. B, AGS-GFP or AGS-fWSX1 
effect on immune cells were analyzed similarly to 3.5A. C, IFNγ expression in CD4, CD8, and 
NK cells was compared in splenocytes co-cultured with either LLC-GFP or LLC-WSX1 tumor 
cells. D, IFNγ expression in CD4, CD8, and NK cells was compared in splenocytes co-cultured 
with either AGS-GFP or AGS-fWSX1 tumor cells. 
 
WSX1 directly affects T cell proliferation. Our findings so far support the idea that 
WSX1 expression in tumors reduces T cell numbers and IFNγ production. Next, we wanted to 
assess whether WSX1 induces T cells death or whether WSX1 inhibits T cells proliferation. To 
address this question, splenocytes were stimulated with CD3 and CD28 in the presence WSX1-
positive tumor cells. After 72 hours, CD4
+
 and CD8
+
 cells were analyzed for expression of 
apoptotic markers: Caspase 8, Caspase 9, and Annexin V. The percentage of CD4
+
 and CD8
+
 
cells expressing apoptotic markers were similar when incubated with WSX1-expressing tumor 
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Figure 3.6. WSX1 induces immunosuppression in a cell contract-dependent manner. A, 
detection of the effect of LLC-GFP or LLC-WSX1 tumor cells on CD4
+ 
T cells in the presence 
or absence of a transwell. Cells were seeded and analyzed similarly as in point 3.5A. B, detection 
of the effect of LLC-GFP or LLC-WSX1 tumor cells on IFNγ expression in CD4+ T cells in the 
presence or absence of a transwell. Cells were seeded and analyzed similarly as in point B. 
 
cells than control cohorts (Fig. 3.7A), suggesting that WSX1 affects T cells proliferation rather 
than apoptosis of T cells.  
As a measure of T cell proliferation, CFSE –labeled splenocytes were co-incubated with 
tumor cells. Cell proliferation was determined on both lymphocytes and CD4
+
Foxp3
-
 
populations. Since we cannot rule out the possibility that tumor cells affect T cell proliferation 
via APC cells, total splenocytes rather than purified T cells were used. Analysis of CFSE 
staining showed that lymphocyte cell proliferation was affected, where 29% of lymphocytes in 
the presence of LLC-GFP had divided more than twice, while in the presence of LLC-WSX1, 
none of the cells had divided more than twice. Similar results were obtained for CD4
+
Foxp3
-
 
cells, as a larger percentage of non-dividing cells were seen in presence of LLC-WSX1 than 
LLC-GFP tumor cells (21% vs. 16%, Fig. 7C). More importantly, only 10% had divided more 
than once in the presence of LLC-GFP, and none had divided in the presence of WSX1.  
This data further supports the idea that WSX1 affects T cell proliferation but does not 
address the question of whether WSX1-tumors affect T cell proliferation directly or indirectly 
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Figure 3.7. WSX1 directly affects T cell proliferation. A, comparison of apoptosis markers in 
CD4 and CD8 T cells when co-incubated with LLC-GFP or LLC-WSX1 tumor cells. 
Splenocytes and tumor cells are co-incubated as in Fig. 5A, and then cells gated for CD4
+
 (left) 
or CD8
+ 
(right) markers were analyzed for Caspase 8, Caspase 9, or double positive cells in both 
Annexin V and propidium iodine (PI) expression. B, comparison the differences in splenocytes 
cell numbers and the differences in lymphocyte proliferation in the presence of either LLC-GFP 
or LLC-WSX1 tumor cells. Splenocytes and tumor cells were co-incubated as in Fig. 5A, and 
viable splenocytes were counted via tryptophan blue exclusion (left). In the right panel, CFSE-
labeled splenocytes were seeded as in Fig. 5A, and then cells gated for lymphocytes (based on 
size) were analyzed for CFSE dilution. C, CFSE-labeled splenocytes were seeded as in Fig. 5A, 
and cells gated on expression of CD4 but excluded from FOXP3 expression were analyzed for 
CFSE dilution.  D, comparison of CD3
+
 T cell numbers and proliferation in the presence of 
either LLC-GFP or LLC-WSX1 tumor cells. CD3
+
 T cells were purified, labeled with CFSE, co-
incubated with either LLC-GFP or LLC-WSX1 at a 1:10 or 1:40 tumor to T cell ratio, and then 
analyzed for CFSE dilution. E, Purified CD3
+
T cells were CFSE- labeled and injected 
systemically into LLC-GFP or LLC-WSX1 tumor-bearing mice. 6 days post-transfer, CFSE-
positive lymphocytes within the tumor microenvironment were analyzed. Points, mean; bars, 
SE. *, P <0.05. 
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via another cell type such as APC. Thus, purified CFSE-labeled CD3
+
 cells were directly co-
incubated with tumor cells expressing either GFP or WSX1 at different ratios. After 48 hours, 
the ratio of CD3
+
 cells/tumor cells was significantly reduced by WSX1 (Fig. 3.7D, left). 
Moreover, in LLC-WSX1, 20% of CD3
+
 cells were non-dividing, whereas in LLC-GFP only 
12% of these cells were non-dividing (Fig. 3.7D, right). Likewise, the number of cells dividing 
more than once was significantly reduced by WSX1 (25% vs. 8%, p<0.05), further 
demonstrating that WSX1 expression in tumor cells directly affects T cell proliferation. Such 
inhibition was also shown in vivo, as systemic transfer of CFSE-labeled CD3
+
 T cells was 
approximately 10 fold lower in the tumor microenvironment of LLC-WSX1 than in control GPF 
tumor-bearing mice 6 days post-transfer (Fig. 3.7E). 
DISCUSSION 
According to the CDC, lung cancer remains the major cause of cancer-related deaths in 
United States. In 2006, the number of deaths of cancer patients related to lung cancer was larger 
than the sum of breast, colon, and prostate cancer combined. Such phenomenon is partly due to 
the fact that these tumors are highly unresponsive to immunological-based therapies (28, 29). 
This trend is partly explained by the high immunosuppressive tumor microenvironment in these 
tumors (30, 31), which in return induces a tolerant state and poor ability to respond to any 
immune-based therapies. Revealing these suppressive mechanisms is critical for developing 
effective immune therapies in treating both primary and metastatic tumors by reversing the 
tumor tolerance.  
Several immune suppressive molecules secreted or expressed from tumor associated 
macrophages, myeloid-derived suppressor cells, tolerogenic DC cells, Treg cells, and tumor cells 
in the tumor microenvironment may be responsible for the suppressive effect (32-34).  For the 
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first time, this study shows that WSX1 expression in tumors stimulates immune suppression 
(Fig. 3.1) and this receptor might be a new target in immune therapy to reverse tumor tolerance. 
The underlying mechanism by which the known immune suppressive molecules regulate 
immune suppression have been previously explored. It was found that upregulation of PD-L1 in 
multiple tumors, which, upon binding to its receptor expressed in activated T cells, induces 
apoptosis, anergy, and exhaustion of effector or memory T cells (35-37). Expression of 
indoleamine 2,3-dioxygenase (IDO) by tumor cells is another such mechanism (38, 39). 
Upregulation of this tryptophan-degrading enzyme induces tryptophan depletion in the local 
surroundings, which severely downregulates different facets of immune responses, such as 
effector T cell population, DC cells, and NK cells.  Moreover, tumor cells induce expression of 
co-stimulatory receptors such as CD80 and CD86, inducing proliferation of not only effector T 
cells but also and more importantly induction and maintenance of Treg cells via CTLA-4 (40).  
In this study, WSX1 plays a crucial role in regulating the communication between tumor 
cells and immune cells. This communication is via a direct interaction between WSX1 
expressing tumor cells and T cells, resulting in inhibition of IFNγ production and T cell 
proliferation (Fig. 3.4), and this mechanism occurs both in vitro and in vivo (Fig. 3.4 and 3.5). 
The communication between WSX1 expressing tumor cells and T cells is seen not only in an 
aggressive lung cancer model, LLC, but also in melanoma cell line AGS, indicating that WSX1 
is as important as other immune suppressive molecules in regulating anti-tumor immune 
responses. Since most human tumor cells express high levels of WSX1 (16), such an immune-
suppressive mechanism may be very common in human patients and needs to be tested in future 
studies.  
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Similar to these receptors, WSX1 attenuates the immune response in the tumor 
microenvironment and in other distal organs such as the spleen, characterized by lower numbers 
of T cells and NK cells. This study further confirms that WSX1 inhibits T cell proliferation in 
vitro and in vivo. WSX1 inhibits the number of CFSE-positive T cells in the tumor 
microenvironment. The decreased presence of CFSE-positive T cells in the tumor 
microenvironment is not due to T cell infiltration in tumors, as the number of CFSE-labeled T 
cells after 16 hours post-injection were similar between GFP and WSX1- positive tumors (data 
not shown). In these tumor models, the function of this receptor is directly associated with 
immune suppression but does not affect the intrinsic pathways within tumor cells. In contrast, 
tumor cells which overexpress WSX1 grow slower in multiple tumor models and have lower 
clonogenic ability when compared to control cohorts (Fig. 3.1) (16). Additionally, WSX1 cannot 
promote tumor growth in immune-compromised mice which once again confirms the ability of 
WSX1 to influence immune tolerance (Fig. 3.4A). 
A hallmark of an effective immune response is the ability of T and NK cells to effectively 
secrete IFNγ. Secretion of IFNγ plays a key role in macrophage activation, inflammation, and 
host defense against intracellular pathogens, T helper 1 (Th1) cell responses, tumor surveillance, 
and immunoediting (41). WSX1-positive tumors cells have an inhibitory affect on the number of 
T cells and the percentage of T and NK cells secreting IFNγ, similar to the effect of CTLA and 
PD-1 ligands (35, 42, 43). Indeed, such inhibition is also observed in both tested tumor models.  
WSX1 expressing tumor cells induce tumor tolerance via direct cell-contact inhibition. 
The ability of WSX1 to reduce the number of T and NK cells and cytokine production is 
reversed in the presence of transwell barrier. Such an observation suggests that WSX1 does not 
inhibit T cells proliferation via expression of IL10 or TGFβ directly but needs another receptor 
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on immune cells. That the physical separation between tumors and immune cells reverses 
tolerogenic properties of WSX1 and tumor cells directly affect the proliferation of T cells 
suggests the existence of another inhibitory receptor on activated T cells. Although we cannot 
exclude that WSX1 could affect the expression of either CTLA or PD-1 ligands in tumor cells, 
which in turn act on T cells, this hypothesis is not as plausible since even WSX1 lacking the 
intracellular domain promotes tumor growth. Besides directly affecting T cells, NK cell number 
and the ability of these cells to produce IFNγ are affected by WSX1. In SCID mice the NK cell 
population is intact and WSX1’s ability to promote tumors is abolished (Fig. 3.4), which 
suggests that T cells are the primary cells affected by WSX1. Conversely, the effect on NK cells 
might be indirect via T cells or another cell type such as tolerogenic APC cells or Treg cells, 
both of which play crucial roles in tolerance and cancer (44-46). So, finding out how WSX1 
affects T cells and their subsequent roles on other cells would be of crucial interest in developing 
effective strategies to break tolerance. 
Similar to our previous work, we again see that WSX1 promotes tumor growth 
independently of IL27 (16). Tumor cells expressing a truncated version of WSX1 that lacks the 
intracellular domain, which renders IL27 unable to signal into the tumor cells, grow much faster 
than tumor cells containing full-length WSX1. This discovery reaffirms other findings that IL27 
inhibits tumor growth (22). To further exclude the concept that WSX1 promotes tumor growth 
by acting as a sequestering receptor, therefore limiting IL27 from signaling into the host, we 
used TCCR
-/-
 mice so IL27 is unable to signal into immune cells. Even in the absence of IL27 
signaling in immune cells, WSX1 expression in tumors retains the ability to promote tumor 
growth. Others have also found that WSX1 does promote tumor growth in leukemia tumor 
models; however, this was the case only if the JAK2 was mutated in these tumors (47). Under 
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this special condition, WSX1 was acting as a scaffold receptor to maintain activation of JAK2. 
This mechanism does not explain our observation, as the truncated WSX1 receptor enhances 
tumor growth, regardless of whether it can serve as a scaffold receptor or not for JAK2. Also, 
WSX1 attenuates cell proliferation without IL27. In figure 6, direct co-incubation between 
WSX1-positive tumor cells and purified CD3
+
 T cells inhibits T cells proliferation, whereas 
neither T cells nor tumor cells express IL27. In summary, WSX1 has a function in tumor biology 
independent of IL27; therefore, caution should be exerted in interpreting any data from TCCR
-/-
, 
as multiple functions that were previously attributed to IL27 might actually be applied to WSX1 
itself.  
Downregulation of the NKG2D receptor in immune cells is another immune-evasive 
mechanism: immunosuppressive CD4
+
NKG2D 
+
 cells or shedding of NKG2D ligands leads to 
immune evasion via downregulation of NKG2D receptors in NK
+
 or CD8
+
 cells (24, 25, 27). 
Previously, our group identified a connection between WSX1 and NKG2D ligand expression in 
two independent tumor models, AT84 and TC1 (16). There is no downregulation of the NKG2D 
receptor in NK
+
 and CD8
+
, and there is a higher percentage of NKG2D positive NK
+
 and CD8
+
 
cells. WSX1 did not change immunosuppressive CD4
+
NKG2D
+
 cells, and, more importantly, the 
levels of NKG2D ligands are similar between GFP-expressing and WSX1expressing LLC 
tumors. Moreover, there is higher expression of both extracellular and total NKG2D in 
lymphocytes in WSX1-positive tumor bearing mice. 
Identifying the mechanism which determines whether WSX1 inhibits tumor growth via 
induction of the NKG2D ligand, as in TC1 and AT84 tumors, or inhibits T cell proliferation and 
cytokine production resulting in immune tolerance, as in LLC and AGS, is of great interest. Of 
further importance would be to find out how WSX1 interacts with T cells, and, specifically, 
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which mechanisms this receptor uses to limit T cell population expansion. Understanding such 
regulatory mechanisms may provide new targets for potential therapies in multiple fields such as 
cancer, anti-aging, autoimmune diseases, and transplant acceptance. In summary, this report 
identifies for the first time that WSX1, independently of IL27, promotes tumor growth and 
immune tolerance in multiple tumor models via direct inhibition of T cell proliferation and 
cytokine production both in the tumor microenvironment and at distal sites. 
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OVERALL SUMMARY OF FINDINGS 
It is well known that a strong immune response inhibits tumor growth and metastasis. 
Expression of pro-inflammatory cytokines in the tumor microenvironment such as IL12 and 
IFNγ inhibit tumor growth in a variety of mouse and human tumors models, while expression of 
anti-inflammatory cytokines such as IL10 and TGFβ are associated with disease relapse and 
progression (1-4). Therefore, elucidating such immune suppressive mechanisms is critical in 
developing effective immune therapies in treating tumors. The interleukin (IL) 27 receptor 
WSX1 is expressed in immune cells and induces an IL27-dependent immune response (5). 
Opposing this conventional dogma, our initial results revealed a much higher level of WSX1 
expression in multiple types of epithelial tumor cells when compared to normal epithelial cells, 
suggesting a role for WSX1 in tumor development, thus a possible target in cancer immune-
therapy (6). 
In chapter 2, we reveal that expression of exogenous WSX1 in epithelial tumor cells 
suppresses tumorigenicity in vitro and inhibits tumor growth in vivo. Different from the role of 
WSX1 in immune cells, the antitumor activity of WSX1 in epithelial tumor cells is independent 
of IL27 signaling and is mainly dependent on NK cell surveillance. Deficiency of either the IL27 
subunit Epstein–Barr virus-induced gene 3 (EBI3) or WSX1 in the host animals had no effect on 
tumor growth inhibition induced by WSX1 expression in tumor cells. Expression of WSX1 in 
epithelial tumor cells enhances NK cell cytolytic activity against tumor cells, while the absence 
of functional NK cells impairs the WSX1-mediated inhibition of epithelial tumor growth. The 
underlying mechanism by which WSX1 expression in tumor cells enhances NK cytolytic activity 
is dependent on upregulation of NKG2D ligand expression. Our results reveal an IL27-
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independent function of WSX1—sensitizing NK cell-mediated antitumor surveillance via an 
NKG2D-dependent mechanism. 
In chapter 3, further analysis of WSX1 expression in tumors reveals a paradox: 
expression of WSX1 in Lewis Lung Carcinoma (LLC) cells enhances tumor growth in vivo, but 
it reduces tumor cell proliferation and clonogenic ability of these cells in vitro, which is also 
observed in the TC1 and AT84 cell lines. The phenomenon in LLC tumors is dependent on 
suppression of the immune response, as WSX1-positive tumors inhibit T cell proliferation and 
the ability of T and NK cells to produce IFNγ. Such observations were confirmed both in vivo 
and in vitro. This effect is initiated via direct contact between tumor and immune cells. Such 
immune suppression is mediated independently of the NKG2D and IL27 pathway: WSX1 
expression does not induce NKG2D ligand expression, and the lack of IL27 signaling in either 
the tumor or the host does not reverse the ability of WSX1-positive tumors to promote tumor 
growth. Thus, our discovery reveals a new channel through which cells and host immune cells 
communicate to promote tumor development. 
SIGNIFICANCE OF RESEARCH 
In 1909, Paul Aldrich predicted that the immune system would inhibit the initiation of 
tumorigenesis; otherwise, the rate of tumorigenesis would be much higher than the current rate. 
One of the key immune populations in immunosurveillance consists of NK cells, as they possess 
the ability to “see” and destroy the transformed cells; therefore, harnessing the ability of these 
cells to destroy tumors is an attractive strategy in cancer patients. The NKG2D-NKG2D ligand 
pathway is a dominant pathway that makes tumor cells visible to the NK cell attack (7). 
Modulating the expression of NKG2D ligands in the tumor cells will enhance the ability of NK 
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cells to eradicate tumors. Thus, understanding how these ligands are upregulated in tumors will 
lead to better strategies in developing anti-cancer therapies.  
In the past decade, however, evidence has shown that the complex relationship between 
tumors and immune cells is not a one way street (8, 9). Further iresearch into this relationship 
has shown that immune cells play a crucial and necessary role in tumor progression. Indeed, 
several reports have shown that although immune cells can destroy transformed cells, certain 
immune cells in the tumor microenvironment can also promote escape of tumor cells from the 
immune system, and/or downregulate the transition from a pro-inflammatory immune response 
into a tolerant state (10). Multiple tumors have adapted such pathways to downregulate the 
immune response, thus facilitating tumor growth and immune evasion. Several regulatory 
mechanisms include: upregulation of PD-1L, IDO, galectin 3, co-stimulatory receptors CD80 
and CD86, downregulation of MHC class I and so forth (11-16); .  
So far, no current link between WSX1 expression in tumors and its affect on the tumor 
microenvironment has been reported in the literature. For the first time we introduce WSX1 
expression in tumors as a modulator of immune cells. Overexpression of WSX1 in tumors has a 
complex role: WSX1 expression in TC1 and AT84 epithelial tumors inhibits tumor growth via an 
NKG2D-dependent mechanism, while in LLC and AGS tumors WSX1 promotes tumor growth 
and induces immune tolerance via a T cell dependent mechanism. Several genes have such a 
complex nature in carcinogenesis. TGFβ is a clear example as it was definitively shown in 
multiple models of skin carcinogenesis to inhibit papilloma growth, while expression at a later 
stage promotes rapid epithelial-mesenchymal transition and metastasis (17-19). Similarly, SIRT1 
has been shown to downregulate p53 activity and act as a tumor suppressor in cells where p53 is 
mutated (20) 
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 The role of NKG2D ligand expression in tumors as a sensor of transformation has been 
well documented in several chemically-induced tumors; however, other than ATM/ATR 
pathways, additional mechanisms exist that detect alterations in tumor cells (21), (22). Here we 
show another such mechanism and link WSX1 expression in tumor cells to NKG2D ligand 
expression. Similar results are shown in two independent tumor models, suggesting that WSX1 
indeed has such a role. Thus, tumors expressing WSX1 could translate into a good tumor 
prognostic marker for NK cell therapy. 
T cell anergy is a common occurrence in tumor microenvironment (23). As tumors 
progress to more malignant stages, the cells go through a journey that requires the acquisition of 
intrinsic and extrinsic characteristics that promote tumor growth. One of such mechanisms to 
induce T cell anergy is upregulation of PD-1L or IDO by tumors cells (12, 14, 15). Here, we 
describe another such event and we show that WSX1 induces immune suppression in both LLC 
and AGS tumor models via reduction of T and NK cells at the tumor microenvironment and at 
distal sites. Therefore, together with previously mentioned immune-evasion mechanisms such as 
upregulation in tumors of PD-L1 or IDO expression has on T cell function, WSX1 shows similar 
properties in immune evasion. Moreover, since multiple human samples have high expression of 
WSX1, it will certainly remain a focus for therapeutic purposes. 
In addition to the fact that WSX1 expression affects immune cells and the tumor 
microenvironment, these studies have made significant contributions to understanding IL27 
biology. In both chapters 2 and 3, we present clear evidence that although WSX1 is a receptor 
for IL27, this receptor has functions independent of IL27. As WSX1 expression in tumor cells 
shows that it inhibits T cells proliferation directly without the need of IL27; however, caution 
should be exerted in interpreting any data from TCCR-/-, since multiple functions that were 
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previously attributed to IL27 might actually belong to WSX1. Indeed, many different phenotypes 
are observed between EBI3-/- (IL27 subunit knockout) and TCCR-/-  mice (24, 25). Although 
many of these differences could be attributed to either IL35 or p28/CLF complex, WSX1 could 
also attribute to these differences. Therefore, better knockout models are needed to sort out the 
differences between the subunits and the receptors of IL12 family. 
FUTURE DIRECTION 
Although we believe that our aforementioned studies have made significant contributions 
in identifying novel pathways through which tumors cells affect the tumor microenvironment, 
further studies are required to better understand the underlying mechanisms of the molecular 
switch for WSX1 to inhibit tumor growth in certain tumors, such as TC1 and AT84, while 
enhancing tumor growth in others, such as LLC, and AGS. Our data shows that tumors 
expressing WSX1 affect not only T cells but also NK cells. This observation prompts us to ask 
whether WSX1-positive tumor cells have a similar effect on other immunosuppressive cells such 
as myeloid-derived suppressor cells, tolerogenic dendritic cells, and tumor associated 
macrophages. Moreover, the intricacy of cross-talk among immune cells creates further interest 
in investigating how T cells in the presence of WSX1-positive tumors affect other cell 
populations, such as DC, NK cells, MSDC, and immune inhibitory factors such as IL10, TGFβ, 
VEGF and so forth.  
  WSX1 function as a tumor promoter needs cell-to-cell contact with immune cells and 
tumor cells, but the downstream effects on T cells are unclear, suggesting that WSX1 has a 
corresponding receptor in T cells, and signaling via this receptor induces T cells tolerance. 
Further studies could explore the identity of this receptor, and how this receptor affects TCR 
signaling, SHP-1 and SHP-2 phosphatases, and IL2 production from T cells. In summary, better 
92 
 
understanding of how WSX1 expression affects immune cells and tumor growth will lead to 
better and more effective therapies for cancer patients.  
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